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ABSTRACT 
 
Selenium is an essential trace element that is critical for human health. The biological effects of 
selenium are largely mediated by selenoproteins, a unique class of proteins that contain 
selenocysteine (Sec) as an integral part of their polypeptide chain. Selenoprotein M 
(SELENOM) is an ER-resident thiol-disulfide oxidoreductase that is most abundant in the brain. 
It contains a thioredoxin-like domain (cysteine-X-X-selenocysteine) that catalyzes thiol-disulfide 
exchange. It has been reported that SELENOM has neuroprotective functions and is implicated 
in regulation of Ca2+ homeostasis. Our group previously published that Selenom-/- mice display 
increased weight gain, elevated white adipose tissue deposition, and impaired hypothalamic 
leptin sensitivity compared to wild-type mice, suggesting a role for SELENOM in energy 
homeostasis. Therefore, we performed a series of studies using in vivo and in vitro models to 
investigate the specific influence of SELENOM on hypothalamic leptin signaling, ER stress, and 
Ca2+ signaling. The evidence gathered in this study revealed that SELENOM promotes 
hypothalamic leptin signaling, inhibits ER stress, and regulates Ca2+ influx. To further delineate 
the underlying mechanism, we then assessed the subcellular localization and binding partners 
of SELENOM. Using co-immunoprecipitation and liquid chromatography–mass 
spectrometry/mass spectrometry (LC-MS/MS) to screen for SELENOM-binding partners, we 
discovered and verified two proteins, microtubule associated protein 6 (MAP6) and choline-
phosphate cytidylyltransferase 1 alpha (PCYT1A). In addition, we found that SELENOM 
localizes not only in ER but also in mitochondria-associated ER-membranes (MAMs), 
suggesting a potential role of SELENOM in regulation of Ca2+ signaling. Finally, we performed 
microarray analysis using both Selenom-/- hypothalamic tissue and mHypoE-44 cells to identify 
the genes and signaling pathways most affected by SELENOM. Our results revealed 11 genes 
that were significantly altered by SELENOM deficiency, including thioredoxin-interacting protein 
(TXNIP), a negative regulator of the thioredoxin (TXN) system. SELENOM deficiency also 
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significantly reduced TXN activity in both hypothalamic tissue and mHypoE-44 cells. In 
summary, our studies reveal that SELENOM promotes hypothalamic leptin signaling, potentially 
due to its functions in ER stress, Ca2+ signaling, and the hypothalamic TXN system. In addition, 
we further determined that SELENOM localizes in MAMs and interacts with MAP6 and 
PCYT1A, suggesting an important role in MAMs-modulated Ca2+ homeostasis.  
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CHAPTER 1.  INTRODUCTION 
 
Selenium  
   Selenium (Se) is an essential trace element that is critical for human health. It was first discovered 
and named by a Swedish chemist, Jöns Jacob Berzelius, as a by-product from sulfuric acid production in 
1817. In the environment, Se can be found naturally in water, soil, and a variety of foods. Foods rich in Se 
include Brazil nuts, seafood, grain, cereals, organ meats, some green vegetables, and shiitake 
mushrooms. Se concentration in plants depends on the Se content in the surrounding soil, which varies 
tremendously between areas worldwide, ranging from deficiency (close to zero) to 1250 mg/kg [1-4]. 
Regions with especially high Se levels in the soil include Enshi County in China, North and South Dakota 
in the USA, and some parts of Ireland and Colombia. In Enshi County, plants will uptake and accumulate 
high levels of Se from the soil, leading to a potential risk of selenosis for local residents [5, 6]. There are 
also areas with Se deficient soil, such as Congo, New Zealand, Finland, some regions of Arizona and 
Montana in the USA, a wide belt extending from northeast to southwest parts of China, and central Serbia 
[7-9]. Other factors that contribute to plant Se uptake from soil include the relative concentrations of other 
elements (iron, sulphur, and aluminum) and soil pH [10, 11]. Se deficiency is implicated in Keshan 
disease, Kashin-Beck disease, and myxedematous endemic cretinism, which are characterized by 
congestive cardiomyopathy, osteoarthropathy, and mental retardation, respectively [12-15]. In addition, 
Se deficiency also contributes to decreased thyroid function, metabolism disorders, immune dysfunction, 
several neurological conditions, increased cancer risk, and male infertility [2, 3]. In the environment, Se is 
present as inorganic (selenite, selenate, selenide, elemental Se) and organic chemical forms, mainly 
including selenomethionine (SeMet) and selenocysteine (Sec) [16, 17]. Both organic and inorganic forms 
of Se can be absorbed in small intestine and utilized in various body tissues [18]. These Se metabolites 
are taken up and absorbed primarily by enterocytes with varying efficiency, depending on the presence of 
other trace elements and the specific biochemical forms of Se [19-23]. However, the mechanisms by 
which these Se metabolites are absorbed and processed vary. Selenite is believed to passively diffuse 
across the plasma membrane while selenate is absorbed via an sodium-mediated carrier mechanism  
and reduced to selenite before being further metabolized [20, 24].  The organic form of Se, SeMet, is 
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absorbed by methionine (Met) transporters and incorporated into proteins at the methionine positions in 
direct proportion to the relative content of Met [25]. Together with the existing intracellular Se pool, these 
Se sources will be metabolized via different pathways and eventually become selenide, which is the direct 
precursor for selenocysteine (Sec) biosynthesis. 
     A growing interest has emerged over past decades in the correlation between Se intake and human 
health, which was initiated with ground breaking experiments in rodents [26]. Researchers found that the 
range between therapeutic and toxic doses of Se is very narrow and that the effects of Se 
supplementation depend on multiple factors, including ingested forms and dose of Se [27-30]. In 1989, 
the World Health Organization suggested a recommended daily allowance (RDA) of Se, 55 μg for women 
and 70 μg for men. However, different countries have established their own recommendations of Se 
intake. Since 2000, the US RDA for Se has been changed to 55 μg per day for both women and men, 
whereas Tolerable Upper Intake Level (UL) is 400 μg per day by the National Academies of Science’s 
Institution of Medicine. In some European countries, such as the UK, Denmark, Norway, and Germany, 
the RDA for Se ranges from 50 μg to 75 μg per day. Different from other countries, Japan established a 
much lower RDA at 25 μg and 30 μg per day for women and men, respectively. These recommendations 
were established based on the minimum Se level required to obtain optimal plasma glutathione 
peroxidase (GPx) activity [31, 32]. However, recent studies indicate that selenoprotein P (SELENOP) may 
be a better indicator for Se status since higher Se intake is required for optimal SELENOP expression 
[33]. Human studies provide evidence of a U-shaped association between Se intake and various health 
risks [34, 35].  
 
Selenoproteins 
   Se carries out important biological functions through its incorporation into selenoproteins in the form 
of the 21st amino acid, Sec, which was first discovered in the 1970s [36].  In humans, there are 25 distinct 
selenoproteins that are widely distributed in various organs. These proteins include the glutathione 
peroxidases (GPxs), thioredoxin reductases (TXNRDs), iodothyronine deiodinases (Dios), 
selenophosphate synthase 2 (SPS2), and several additional Sec-containing proteins. Other than the 
aforementioned selenoenzymes, the functions of most of the members of this class of proteins are not 
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well understood, but are currently under investigation.  A list of the 25 human selenoproteins and known 
functions is presented in Table1. 
 
Selenoprotein Synthesis 
   To understand the distinct features and structures of selenoproteins, first, we need to understand the 
mechanisms by which Sec is incorporated into selenoproteins. Sec incorporation into proteins is essential 
for many fundamental functions in humans [37]. The UGA codon, normally a stop codon, codes for Sec in 
the coding regions of selenoprotein genes [38]. Cis-acting factors and trans-acting factors bring a 
selenocysteyl-tRNA (Sec-tRNA[Ser]Sec ) to the ribosome. This Sec-tRNA[Ser]Sec recognizes the 
selenocysteine-insertion codon (UGA) in the coding region of selenoprotein mRNAs. However, Sec-
tRNA[Ser]Sec alone is not sufficient to decode UGA codons as Sec.  A specific RNA stem-loop structure in 
the 3′ untranslated region (3′ UTR) of selenoprotein mRNAs, termed a Sec insertion sequence (SECIS) 
element, is also required. The SECIS element  was first discovered and defined in iodothyronine 
deiodinase 1 (Dio1) [39]. The selenoprotein translation process also requires SECIS binding protein 2 
(SBP2) and Sec-specific elongation factor (eEFSec) [40-43]. However, some fundamental questions of 
this distinct process still remain unclear, particularly the functions of other factors, such as the SECIS 
binding protein 2 like protein (SECISBP2L) [41, 44], eukaryotic initiation factor 4a3 (eIF4A3) [45], and 
ribosomal protein L30 (RPL30) [46]. 
 
Selenoprotein Families 
   Most selenoproteins display antioxidant functions through the amino acid, Sec. For example, GPx 
and TXNRD family members are well characterized as antioxidant enzymes that regulate redox 
homeostasis and protect organisms from damage caused by reactive oxygen species (ROS).  
   GPxs were the first identified mammalian proteins that incorporate Se as Sec into the active site [47]. 
The GPx family reduces hydrogen peroxide and organic hydroperoxides, functioning in a protective role 
against oxidative stress. In humans, there are seven GPx proteins of which five are selenoproteins. 
These Sec-containing GPxs (GPx1-4, GPx6) are distributed in different tissues and utilize different 
substrates for peroxide removal, such as hydrogen peroxide, fatty acid hydroperoxides, phospholipid 
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hydroperoxides, and cholesterol hydroperoxides. GPxs are essential components in the human 
antioxidant system and their loss has been linked to Keshan disease, metabolic syndrome, and different 
types of cancer. Interestingly, GPx1-/- and GPx2-/- mice are healthy and fertile under normal conditions, 
whereas GPx4-/- mice are embryonic lethal [48, 49]. GPx4 directly reduces phospholipid hydroperoxides 
and cholesterol hydroperoxides. Moreover, it is also involved in male fertility and sperm maturation as a 
redox-active enzyme in spermatids. 
   TXNRD, along with thioredoxin (TXN) and nicotinamide adenine dinucleotide phosphate (NADPH), 
comprises the TXN system, which contributes to redox homeostasis and is essential for life. There are 
three mammalian TXNRDs: TXNRD 1 localized to the cytosol, TXNRD 2 localized to mitochondria, and 
testis-specific TXNRD 3. They catalyze the reduction of TXN using electrons transferred from NADPH. 
The TXN system plays a critical role in development, as deletion of TXN, TXNRD1, or TXNRD2 in mice 
results in embryonic death [50-53]. 
   The Dio family consists of three different Sec-containing oxidoreductases, Dio1, Dio2 and Dio3, which 
regulate the activity of thyroid hormones. Dio1 and Dio2 catalyze the activation of thyroxine (T4) into 3, 5, 
3-triiodothyronine (T3), whereas Dio3 inactivates T4 into reverse T3, a metabolically inactive form. 
Therefore, Dios are implicated in diseases with impaired thyroid hormone metabolism, such as 
hyperthyroidism and hypothyroidism [54]. 
   Selenoprotein P (SELENOP) is a secreted protein that contains two domains, an N-terminal domain 
with one Sec in a UXXC redox motif and a C-terminal domain containing 9 Secs. The high selenium 
content of SELENOP indicates that it is involved in selenium transport or storage [55]. The liver produces 
the highest amounts of SELENOP, and exports the protein to other organs, such as the brain, testis, and 
kidney. Apolipoprotein E receptor 2 (ApoER2) and megalin bind to SELENOP and mediate its uptake into 
testis and kidney, respectively [56, 57]. 
 
Selenoproteins in Metabolic Disorders 
   Selenoproteins have a wide range of effects documented in literature, including cancer prevention, 
preventing heart diseases, antioxidant properties, regulating immune function, thyroid hormone activation, 
and insulin sensitivity regulation. Animal and human studies have revealed complex correlations between 
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selenoproteins and metabolic disorders. A study in a high-fat diet/STZ-induced T2D rat model has 
revealed that Se supplementation (180-500µg/Kg/Day) can reduce blood glucose and cholesterol level 
[58]. In clinical studies, a positive correlation of low Se level with T2D incidence has been reported in 
senior French men and samples from Spain [59, 60]. However, these disparate findings lack consensus. 
Other randomized studies have revealed a positive correlation between Se intake and metabolism 
disorders [61-63]. The roles of individual selenoproteins in metabolism may explain some of the 
controversial findings in these human studies. 
   GPx1, or cytosolic GPx, is expressed ubiquitously. Transgenic mice overexpressing GPx1 develop 
insulin resistance, hyperglycemia, elevated body weight, hyperinsulinemia, and obesity [64], indicating 
that high levels of GPx1 may interfere with insulin function. Furthermore, the hyperinsulinemia was not 
corrected when these mice were challenged with a Se deficient diet [65]. This finding in GPx1-
overexpressing mice is consistent with results from another study in which elevated GPx1 was associated 
with mild insulin resistance in pregnant women [66, 67]. The expression of GPx1 is known to be sensitive 
to Se intake. Rats with Se supplementation had high levels of GPx1 in the liver and showed increased 
protein tyrosine phosphatase 1B (PTP1B) activities, a known antagonist of insulin signaling [68]. 
Moreover, GPx1-/- mice were protected from high-fat-diet-induced insulin resistance due to increased 
ROS, leading to the oxidation and inhibition of phosphatase and tensin homolog (PTEN), which 
terminates phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K) signaling. With GPx1 deficiency, 
excessive ROS inactivated pancreatic protein tyrosine phosphatase N2 (PTPN2), promoted signal 
transducer and activator of transcription 1 (Stat1) signaling, and inhibited pancreatic and duodenal 
homeobox-1 (Pdx1) expression. In turn, this signaling cascade inhibited β cell insulin secretion and, 
consequently, improved pancreatic insulin signaling and suppressed hepatic glucose production [69]. 
Taken together, the function of GPx1 in metabolic disorders may depend on many factors, including 
tissue-specific GPx1 expression and different development states of T2D. 
   Another selenoprotein involved in the development of T2D is selenoprotein P (SELENOP), a liver 
derived secretory protein. Misu et al. reported that increased hepatic SELENOP mRNA levels positively 
correlated with insulin resistance in humans [70]. Moreover, administration of SELENOP impaired insulin 
signaling and glucose homeostasis in both hepatocytes and myocytes, whereas SELENOP deficiency 
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improved insulin sensitivity and glucose tolerance. This metabolic function of SELENOP is mediated via 
inactivation of adenosine monophosphate-activated protein kinase (AMPK), a positive regulator of insulin 
synthesis and secretion in β cells. The same group also demonstrated that SELENOP deficiency protects 
mice against obesity, insulin resistance, and hypoadiponectinemia resulting from a high fat, high sucrose 
diet [71]. In clinical studies, SELENOP has also been shown to have a strong correlation with glucose 
homeostasis. Serum SELENOP levels were found higher in T2D and prediabetic Korean and Japanese 
patients compared to people with normal glucose tolerance [66] [72]. In addition, in obese and overweight 
subjects in this study, SELENOP levels were higher than those observed in lean subjects, suggesting that 
SELENOP influences carbohydrate metabolism. 
   In addition to GPx1 and SELENOP, other selenoproteins are also implicated in metabolic syndrome 
including GPx4, Dio2, and SELENOT. Dio2-/- mouse model has disruptions in energy metabolism and 
insulin resistance [73]. Studies in vivo and in vitro have revealed that SELENOT is critical for pancreatic β 
cell function and pituitary adenylate cyclase activating polypeptide (PACAP)-induced insulin secretion [74, 
75]. In a recent study, hypothalamic GPx4 levels were found to decrease in response to a high fat and 
high sucrose diet [76]. Conditionally knocking out GPx4 in orexigenic hypothalamic neurons expressing 
agouti-related protein (AgRP) results in increased weight gain and adiposity in male mice. The multi-
faceted correlation between selenoproteins and metabolic disorders is still a focus of interest to obtain a 
clear understanding of Se in metabolic homeostasis. 
 
Selenoprotein M (SELENOM) 
Discovery and Structure 
   SELENOM was first identified in silico in 2002 by Korotkov et al. as a 0.7kb cDNA sequence that 
coded for a new protein in mammalian EST databases [77]. The authors reported that this gene has a 
145-amino acid open reading frame that begins with an AUG codon in a favorable Kozak context and that 
Sec is encoded by the 48th codon. In addition, they also determined that the human analogue of 
SELENOM localizes to chromosome 22 (22q12.2), spanning 3kb with 5 exons and 4 introns. The first 23 
amino acids act as a signal peptide that promotes SELENOM translocation to the ER [77]. The remaining 
parts of SELENOM contain a central two-layer α/β sandwich, consisting of three α-helices and four β-
7 
 
strands, and an ER retention signal tetrapeptide in the C-terminus after helix α3. SELENOM, along with 
several other selenoproteins including SELENOF, SELENOH, SELENOO, SELENOT, SELENOV, and 
SELENOW, contains a TXN-like domain, CXXU (U: Sec), at the active site which catalyzes thiol-disulfide 
exchange. Structure studies of SELENOM using 3D computer modeling determined that the C-terminal 
region of SELENOM is highly flexible and does not assume a regular secondary structure [78, 79]. 
Ferguson et al. suggested that the flexible C-terminal region is a potential binding site of SELENOM for 
protein substrates [78].  
 
Expression 
   The first analysis of SELENOM distribution in mammalian tissues revealed that SELENOM mRNA is 
expressed in the brain, heart, stomach, lung, kidney, and thyroid [77]. Among these tissues, SELENOM is 
most abundant in the brain, with low levels in other organs. Utilizing data from the Allen Brain Atlas, 
Zhang et al. conducted a comparative analysis of selenoprotein gene expression in the mouse brain. It 
was documented that GPx4, SELENOK, SELENOM, SELENOP, SELENOW, and SELENOF have the 
highest mRNA expression in the brain [80]. SELENOM mRNA levels are found highest in the 
hippocampus, specifically the CA1/CA2 regions, the dentate gyrus regions, the main olfactory bulb, and 
the cerebellar cortex [80]. Zhang et al. also performed immunohistochemistry (IHC) and Western blotting 
to confirm protein expression of SELENOM in different brain regions. IHC results showed SELENOM 
expression in the hippocampus and the cerebellar cortex, whereas Western blot analysis revealed high 
levels of SELENOM in whole brain samples and the cerebellar cortex. We conducted Western blot 
analysis on different mouse brain regions and the results revealed that SELENOM protein expression 
was highest in the cerebellum and olfactory bulb. In addition, the hippocampus and cerebral cortex had 
the lowest protein levels of SELENOM, while the hypothalamus and the brain stem had intermediate 
levels. To confirm these findings,  IHC was performed, showing that SELENOM is highly expressed in the 
cerebellar cortex, the arcuate (ARC) and paraventricular nuclei of the hypothalamus, the medial septum, 
the reticular thalamus, the red nucleus, the ventral tegmental area, various auditory brainstem nuclei 
(cochlear nucleus, lateral lemniscus, superior olive), and the CA2/CA3 region of the hippocampus.  
Western blot results of various mouse organs further determined that the pancreas and the pituitary also 
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express high levels of SELENOM, comparable to that of the brain [81]. Interestingly, microarray analysis 
of human cochlea and vestibule revealed that SELENOM was detected as one of 52 genes whose signal 
intensities were 10-fold higher in the cochlea and vestibule than in a mixture of other tissues [82].  
   SELENOM expression can also be regulated by a variety of factors, including various transcription 
factors, Se supplementation, and leptin treatment [83-85]. Potential AP1 transcription factor binding sites 
were found in SELENOM by sequencing the putative transcription initiation regions in human 
selenoproteins [86]. SELENOM has been documented to be upregulated by X-box binding protein 1 
(XBP1s), an ER-stress responsive transcriptional activator [83]. Moreover, the SELENOM mRNA levels 
were reduced by fasting and restored by leptin treatment in the hypothalamic paraventricular nucleus 
(PVN) [84]. Microarray analyses of the Atoh1-specific population of the dorsal neural tube relative to the 
neighboring Neurog1-specific population identified SELENOM as one of the transcripts regulated by 
atonal homolog 1(Atoh1). Atoh1 is a basic helix-loop-helix (bHLH) transcription factor that is critical for the 
formation of different proprioceptive neuronal subtypes [87]. Another important influence on SELENOM 
expression is Se supplementation. A recent study examined the effect of dietary Se deficiency and age 
on Se status and selenoprotein mRNA expression in male and female mice [88]. SELENOM mRNA levels 
were consistently downregulated by dietary selenium deficiency in the kidney and liver of both sexes as 
well as in the heart of the female mice. These results are consistent with the findings from Sunde et al. 
who reported that SELENOM expression was moderately influenced by Se status in the kidney and liver, 
but not as significantly as that of GPx1, SELENOH, and SELENOW [89]. In addition, SELENOM 
expression, as well as that of GPx1, SELENOH, and SELENOW, was found to be regulated by Se status 
in mouse colon [90]. Further, levels of SELENOM mRNA and protein in chicken brain were reduced by 
dietary Se deficiency [91].  
 
Neuroprotective Role 
   Both animal models and cell culture studies have demonstrated that SELENOM has neuroprotective 
properties and contributes to intracellular Ca2+ regulation. Utilizing a transgenic mouse model of 
Alzheimer’s disease expressing a mutant human presenilin-2 (PS2) gene, Hwang et al. found that these 
mice had significantly suppressed expression of SELENOM in the brain [92]. Subsequent studies to 
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determine the neuroprotective function of SELENOM were performed using a new transgenic rat model 
that overexpressed human SELENOM. These transgenic rats had increased levels of antioxidant 
enzymes such as GPx and superoxide dismutase (SOD) in various tissues [93]. Further exploring the 
mechanisms in the antioxidant role of SELENOM revealed that SELENOM overexpression as well as Se 
supplementation significantly activated the extracellular signal-regulated kinase (ERK) signaling pathway, 
inhibited α/γ-secretase activity, and reduced the phosphorylation of Tau protein [94].  
   Studies in vitro also contributed evidence that SELENOM has neuroprotective properties and is 
involved in intracellular Ca2+ homeostasis [95]. SELENOM overexpression in hippocampal HT22 cells 
was associated with reduced superoxide production and apoptotic cell death while SELENOM knockdown 
resulted in a high apoptotic cell death rate. Moreover, overexpression of SELENOM decreased 
intracellular Ca2+ flux induced by hydrogen peroxide, whereas knockdown of SELENOM increased the 
cytosolic Ca2+ levels. The disturbance of Ca2+ homeostasis is a major feature of many central nervous 
system (CNS) disorders, including Alzheimer’s disease. These results indicated that SELENOM regulates 
Ca2+ levels and may protect the brain from oxidative stress [95, 96].  
 
Characterization of the Selenom-/- Mouse 
   The transgenic mouse model with a targeted deletion of the SELENOM gene was generated and 
characterized [81]. These mice were raised on standard laboratory chow with adequate Se (~0.25ppm) 
and compared to wild-type mice on a C57BL/6J background to identify potential functions of this protein 
[81]. Selenom-/- mice displayed normal brain morphology, anxiety-like behavior, motor coordination, and 
cognition. Whereas no cognitive deficits were observed, these mice exhibited increased weight gain and 
elevated white adipose tissue deposition. In addition, serum leptin levels were significantly higher in 
Selenom-/- male mice and this did not correspond with differences in the glucose tolerance or hepatic 
insulin signaling. In a subsequent study, SELENOM was found co-expressed with the leptin receptor in 
neurons of the ARC hypothalamus. Compared to wild-type controls, Selenom-/- mice were found to have 
diminished leptin sensitivity in the ARC hypothalamus, indicating leptin resistance. Food consumption 
was then assessed and observed to be comparable between Selenom-/- mice and controls. Therefore, the 
increase in body weight of the transgenic mice is likely due to diminished energy expenditure and 
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reduced movement. Further studies performed on both genotypes fed a Se-deficient diet (Se 
concentration < 0.01ppm) confirmed the main findings as Selenom-/- mice fed with Se-deficient diet were 
observed to exhibit less movement, increased weight gain, and elevated fat deposition. At the same time, 
glucose tolerance was found to be comparable between wild-type and Selenom-/- mice when fed either a 
normal or Se-deficient diet. Additionally, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis 
was found in the Selenom-/- mice. Leptin is known to promote activation of the HPA axis [97]. Combining 
the findings of increased leptin level and the altered base-line corticosterone levels, the results indicate 
that the relationship between leptin signaling and the HPA axis may be dysregulated by SELENOM 
deficiency. Taken together, these studies provide compelling evidence that SELENOM plays a critical role 
in energy metabolism [81]. However, whether the observed impairments in leptin signaling were the 
primary cause or a secondary response of obesity was not determined. 
 
Central hypothesis 
SELENOM promotes hypothalamic leptin signaling and regulates cytosolic Ca2+ levels. 
 
Specific aims 
Aim 1: Assess the specific roles of SELENOM in leptin signaling, ER stress, and cytosolic Ca2+ 
regulation. Our Selenom-/- mouse model was observed to have increased weight gain and develop leptin 
resistance, suggesting that SELENOM may play an important role in leptin signaling. In addition, 
SELENOM was found co-expressed with the leptin receptor in the arcuate hypothalamus, a region 
involved in energy metabolism and leptin signaling [81]. However, it is still unclear whether this leptin 
resistance is the cause or a secondary complication of the obesity. One predominant underlying cause of 
leptin resistance is ER stress. Moreover, SELENOM was implicated in intracellular Ca2+ regulation [95]. 
Therefore, we hypothesize that SELENOM may promote leptin signaling by inhibiting ER stress and 
regulating cytosolic Ca2+ levels. In this aim, we will perform experiments in vitro and in vivo to assess the 
influence of SELENOM upon leptin signaling, ER stress, and Ca2+ signaling. 
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Aim 2: Determine the subcellular localization and interaction partners of SELENOM. SELENOM is 
an ER-resident protein and implicated in intracellular Ca2+ regulation. We hypothesize that SELENOM 
may reside at the ER/mitochondria interface to regulate Ca2+ trafficking between ER and mitochondria, 
and in turn, regulate mitochondrial metabolism. In addition, we speculate that SELENOM may also 
physically interact with proteins involved in energy metabolism and Ca2+ regulation.  For this aim, we will 
determine the subcellular localization of SELENOM in mouse brain tissue using a well-established 
subcellular fractionation protocol for isolation of mitochondria associated ER-membranes (MAMs). In 
further experiments, we will identify SELENOM interaction partners using co-immunoprecipitation and LC-
MS/MS, respectively. 
Aim 3: Determine genes and pathways significantly affected by SELENOM deletion in 
hypothalamus. Selenom-/- mouse model was observed to have significant weight gain, suggesting that 
SELENOM may play an important role in energy metabolism. In addition, SELENOM is highly expressed 
in the hypothalamus, a region critically involved in energy metabolism and leptin signaling. For this aim, 
we will conduct microarray analysis using both hypothalamic tissue and mHypoE-44 cells to the identify 
genes and signaling pathways mostly affected by SELENOM deficiency.  
 
Expected outcomes 
Aim 1: SELENOM will promote leptin signaling, inhibits ER stress, and regulates cytosolic Ca2+ 
levels. We anticipate that leptin treatment will increase SELENOM expression in hypothalamic tissues 
and that SELENOM deficiency will significantly impair the leptin signaling in vivo. In addition, SELENOM 
deficiency is anticipated to promote ER stress and cytosolic Ca2+ level induced by thapsigargin. Finally, 
leptin is anticipated to decrease intracellular Ca2+ levels in control cells and this effect will be abrogated 
by knocking down or knocking out SELENOM. 
Aim 2: SELENOM will interact with proteins involved in Ca2+ homeostasis and energy metabolism 
in the ER, and potentially the MAMs. We anticipate that SELENOM may localize to MAMs and interact 
with proteins involved in energy metabolism and Ca2+ regulation. Some thioredoxin family members and 
ER-resident selenoproteins, including SELENOK and SELENON, have already been indicated in 
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interactions with IP3 receptors and SERCA pumps [98-101]. Therefore, we anticipate that SELENOM 
may interact with IP3 receptors, ryanodine receptors, or SERCA pumps. Further identification of 
SELENOM interaction partners will be performed using co-immunoprecipitation. 
Aim 3: SELENOM deletion will affect genes which are involved in energy metabolism and Ca2+ 
homeostasis. SELENOM have been implicated in cytosolic Ca2+ regulation, leptin signaling, and ER 
stress. Therefore, we anticipate that genes/pathways involved in leptin signaling, calcium regulation, and 
ER stress response may be altered by SELENOM deficiency. Moreover, SELENOM is known as a 
member of TXN superfamily. We also anticipate that genes/pathways involved in antioxidant activities will 
be affected when SELENOM is deficient.  
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Table 1. The Human Selenoproteome and Functions of Selenoproteins.  
Selenoprotein Abbreviation Functions 
Glutathione peroxidases1,2,3,4,6 GPx 1–4,6 Reduce lipid hydroperoxides and free 
hydrogen peroxide 
Iodothyronine Deiodinase 1,2,3 Dio 1,2,3 Thyroid hormone metabolism 
Thioredoxin Reducase 1,2,3 TXNRD 1,2,3 Reduce TXN 
Selenophosphate Synthase 2 SPS2 Sec synthesis 
Methionine Sulfoxide Reductase B1 MsrB1 Catalyze the reduction of methionine-
R-sulfoxide to methionine 
15 kDa-selenoprotein SELENOF Protein folding 
Selenoprotein H SELENOH Genome maintenance and redox 
sensing 
Selenoprotein I SELENOI Lipid metabolism, protein folding 
Selenoprotein K SELENOK Ca2+ flux in immune cells, ER-
associated degradation 
Selenoprotein M SELENOM Ca2+ homeostasis, Energy metabolism 
Selenoprotein N SELENON Ca2+ homeostasis 
Selenoprotein O SELENOO Unknown 
Selenoprotein P SELENOP Transport of Se 
Selenoprotein S SELENOS ER-associated degradation 
Selenoprotein T SELENOT Ca2+ mobilization and neuroendocrine 
secretion 
Selenoprotein V SELENOV Unknown 
Selenoprotein W SELENOW Muscle growth and differentiation 
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CHAPTER 2.   ROLES OF SELENOM IN HYPOTHALAMIC ER STRESS,   
LEPTIN SIGNALING, AND CALCIUM REGULATION 
 
Abstract 
   Selenoprotein M (SELENOM) is an endoplasmic reticulum (ER)-resident thiol-disulfide 
oxidoreductase that is highly expressed in hypothalamic regions involved in leptin signaling and energy 
metabolism. Moreover, Selenom-/- mice exhibit adult-onset obesity, elevated serum leptin levels, and 
diminished leptin sensitivity in hypothalamus, indicating leptin resistance. However, whether SELENOM 
directly influences hypothalamic leptin signaling is yet unclear. One predominant underlying cause of 
leptin resistance is ER stress. Herein, we performed a series of studies using in vivo and in vitro models 
to investigate the specific influence of SELENOM on hypothalamic leptin signaling, ER stress, and Ca2+ 
signaling. The evidence gathered in this study revealed that SELENOM promotes leptin signaling by 
inhibiting ER stress and regulating Ca2+ influx in the hypothalamus.  
 
Introduction 
 The incidence of obesity and type 2 diabetes is growing rapidly and has become an indisputable threat 
to human health worldwide. Selenoproteins are a distinct class of proteins that have been increasingly 
implicated in metabolic disorders [64, 70, 73, 81]. These proteins contain selenocysteine (Sec) as an 
integral part of their polypeptide chain and have protective roles against oxidative stress. SELENOM is an 
ER-resident thiol-disulfide oxidoreductase that is highly expressed in the brain, the hypothalamus in 
particular [77, 80]. As a member of TXN superfamily, SELENOM has an active site consisting of a Sec-
containing TXN-like domain (CXXU) which catalyzes thiol-disulfide exchange reactions. Previous studies 
conducted in vitro suggested that SELENOM has neuroprotective functions and regulates Ca2+ 
homeostasis [95]. Moreover, in our Selenom-/- mouse model, we found increased weight gain, elevated 
white tissue deposition, higher serum leptin levels, and diminished leptin sensitivity, which suggest that 
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SELENOM plays an important role in leptin signaling and energy metabolism [81]. However, the mechanism 
by which SELENOM regulates leptin signaling still remains unknown.  
 Leptin (Ob), a hormone derived from adipose tissue, plays a critical role in the regulation of food intake 
and energy expenditure [102]. The median eminence (ME), which serves as a route for the entry of the 
circulating leptin into the cerebrospinal fluid (CSF), contains a cluster of permeable fenestrated vessels 
[103]. Peripheral leptin first reaches the ME via these fenestrated vessels and binds to the leptin receptors 
expressed by tanycytes, which are specialized hypothalamic glia-like cells. They form a barrier between 
the circulating blood and the 3rd ventricle of the brain, and therefore mediate the transport of leptin into the 
CSF [103]. Once across the ME, leptin binds to transmembrane leptin receptors which are particularly 
concentrated in the arcuate nucleus of the hypothalamus (ARC) [104, 105]. Here leptin acts on two main 
populations of neurons expressing the leptin receptor, propiomelanocortin (POMC)-expressing 
anorexigenic neurons and agouti-related peptide (AgRP) / neuropeptide Y (NPY) / inhibitory γ-aminobutyric 
acid (GABA) -expressing orexigenic neurons. AGRP neurons are well known to positively regulate feeding 
behavior, as brain-specific administration of either AgRP or NPY increases food intake [106, 107]. Both 
AgRP/NPY and POMC neurons project to the melanocortin-4 receptor (MC4R) -expressing neurons in the 
PVN. AgRP is known as a hypothalamus-specific antagonist of MC4R while α-melanocyte stimulating 
hormone (α-MSH), a POMC-derived peptide, activates the MC4R [108]. Therefore, AGRP neurons can 
inversely regulate the melanocortin pathway to reduce satiety and promote food intake [107, 109] Several 
studies have reported that leptin stimulation on AgRP/NPY neurons can decrease cytosolic Ca2+ levels and 
inhibit food intake in vivo [110-113]. Binding with leptin receptor stimulates leptin receptor dimerization and 
activates the autophosphorylation of Janus kinase 2 (JAK2) [114, 115]. JAK2 then phosphorylates two key 
tyrosine residues on leptin receptors, including Y1138, which in turn, activates signal transducer and 
activator of transcription 3 (Stat3) signaling [116]. This leptin signaling pathway is inhibited by two adaptor 
molecules, suppressor of cytokine signaling 3 (SOCS3) and protein tyrosine phosphatase 1B (PTP1B). 
SOCS3 gene expression is upregulated by leptin-induced pStat3 and in turn, mediates the feedback 
inhibition via binding to leptin receptor to block the leptin pathway [117-119]. Another mediator, PTP1B, 
dephosphorylates JAK2 and subsequently diminishes downstream leptin signaling [120] (Figure 2-1). In the 
obese state, Stat3 phosphorylation is poorly stimulated by leptin [121]. Observations from animal models 
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indicate that obesity results from reduced leptin signaling in the brain. This contrasts with increased 
circulating levels of leptin, suggesting that leptin resistance in the brain is a major reason for the failure of 
leptin to reduce feeding behavior and stimulate energy metabolism in obesity. Thus, leptin resistance is a 
major obstacle in treatment of obesity (Fig. 2-2) [122].  
   Although the precise mechanistic basis of leptin resistance remains elusive, some biological defects 
have been proposed to be underlying causes [123]. One predominant underlying cause of leptin resistance 
is ER stress, which leads to altered intracellular Ca2+ signaling and occurs in response to accumulation of 
misfolded proteins and/or Ca2+ depletion within the ER [116, 124]. ER stress can activate a variety of cellular 
processes via signaling pathways termed the unfolded protein response (UPR) in order to restore ER 
functions. UPR is initiated by three different ER-localized proteins: protein kinase-like ER kinase (PERK), 
inositol requiring enzyme 1 (IRE1α), and activating transcription factor-6 (ATF6) [125]. In an unstressed 
state, these three proteins are inactive via association with glucose-regulated protein 78 (GRP78), the most 
abundant chaperone in the ER. In response to accumulation of unfolded proteins, GPR78 dissociates from 
these three ER stress sensors and translocates to the ER lumen for protein folding. This dissociation 
changes the conformation of PERK, IRE1α, and ATF6, leading to their activation (Fig.2-3) [126, 127]. 
Activation of the IRE1α pathway induces splicing of X-box binding protein 1 (XBP1s) mRNA [128] and 
subsequent transcription of molecular chaperones and various genes involved in protein folding, including 
SELENOM [83]. It has also been documented that activation of IRE1α-mediated spliced XBP1 in 
proopiomelanocortin (POMC) neurons protects against diet-induced obesity and improves leptin and insulin 
sensitivity [129]. This evidence suggests that SELENOM may be a positive regulator of leptin signaling by 
regulating sensitivity to ER stress and intracellular Ca2+ signaling. 
   Hence, we performed experiments in vitro and in vivo to assess the influence of SELENOM upon leptin 
signaling, ER stress, and Ca2+ signaling. In these studies, we found that SELENOM is a leptin-responsive 
gene that promotes hypothalamic leptin signaling by regulating ER stress signaling and Ca2+ homeostasis. 
 
Materials and Methods 
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Chemicals and antibodies   
   Thapsigargin and ionomycin were purchased from Sigma. Primary antibodies used in these 
experiments were rabbit anti-phospho-Stat3 Tyr705 (1:1000; Cell Signaling, 9145), rabbit anti-Stat3 
(1:1000; Cell Signaling, 8768), mouse anti-SELENOM (1:500; Santa Cruz, sc-514952), rabbit anti-
phospho-PERK Thr980 (1:1000; Cell Signaling, 3179), mouse anti-CHOP (1:1000; Cell Signaling, 2895), 
and mouse anti-β-Actin(1:5000; Cell Signaling, 3700). Species specific secondary antibodies were 
purchased from LI-COR. Recombinant mouse leptin (Ob) was purchased from R&D Systems and diluted 
to a stock concentration of 1 mg/ml in 20 mM Tris-HCl, pH 8.0.  
 
Animals and leptin challenge 
   Male wild-type and Selenom-/- mice based on a C57BL/6N background were born, bred, and raised 
for 10 weeks in the University of Hawai‘i Vivarium (N≥5 for each group).  The mice were fasted overnight, 
given an intraperitoneal injection of leptin (1 µg/g body weight), and sacrificed 1hr later with CO2 
asphyxiation. Mouse whole brains were removed promptly and immersed in 0.32M ice-cold sucrose for 5-
10 minutes. The brain was then sliced with the ventral side up in a mouse brain slicer matrix with slice 
intervals of 1 mm. Two coronal cuts were made anteriorly at the level of the optic chiasm and posteriorly 3 
mm to the first cut. Under a dissection microscope, this slice was then oriented coronally and the 
hypothalamus was dissected as a trapezoid consisting of the roof of the 3rd ventricle dorsally and the 
fornix laterally, and snap-frozen for later experiments. 
Cell culture 
   The hypothalamic cell line, mHypoE-44, was purchased from Cellutions and grown in Dulbecco's 
Modified Eagle medium (DMEM) (Sigma) with 10% FBS (Invitrogen) (32nM) and 1% penicillin in a 
humidified incubator with 5% CO2 at 37°C. This cell line has a neuronal morphology and is derived and 
immortalized from mouse embryonic day 17 hypothalamic primary cultures by retroviral transfer of SV40 
T-Ag. In addition, mHypoE-44 cells are known to express NPY, AgRP, and leptin receptor [130, 131]. 
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Cells were serum-starved for 4 hours before ER stress induction and leptin treatment. ER stress was 
induced by incubating cells in the presence of 1 µM Tg (Sigma) for 4 hours and leptin treatment was 
carried out by challenging with 100nM leptin for 45 minutes. 
Overexpression of SELENOM and leptin receptors 
   A SELENOM cDNA was synthesized and subcloned into pSelExpress1vector (gift from Vadim 
Gladyshev’s Lab) by GenScript. This SELENOM overexpression plasmid was transfected into mHypoE-
44 cells using Lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells were used for 
experiments 48 hours later (Fig. 2-4C). mHypoE-44 cells express the leptin receptor (ObR). However, we 
found that leptin responses were much stronger (Fig. 2-4D) if cells were transfected with an exogenous 
plasmid expressing the ObR (pObR) (a gift from Christian Bjorbaek’s Lab). Therefore, for all leptin 
stimulation studies, a similar procedure was used to transfect a leptin receptor plasmid. 
Generation of stable hypothalamic cell line with SELENOM shRNA  
   Constructs of short hairpin RNAs (shRNA) for mouse SELENOM and a non-target control were 
subcloned into the pTRIPZ vectors with the Tet-On® inducible system with RFP (Thermo Scientific). 
Hypothalamic cells at 70%-80% confluency were transfected with pTRIPZ vectors with SELENOM or non-
target control shRNA using Lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells were 
selected by media containing 1.5 µg/ml puromycin (Sigma) for the next 7 days. Following the selection 
with puromycin, doxycycline (Clontech Labs) (final concentration=2µg/ml) was added to the culture media 
to 48hr prior to experiments to induce TurboRFP/shRNAmir expression.  RFP expression was examined 
by microscope to evaluate transfection efficiency (Fig. 2-4A). 
CRISPR/Cas9-mediated SELENOM deletion in mHypoE-44 cells 
   CRISPR/Cas9 technology was utilized for CRISPR/Cas9-mediated deletion of SELENOM expression 
in mHypoE-44 cells. Cells were first transfected with pSpCas9 (Addgene) plasmids expressing GFP. After 
selection by fluorescence-activated cell sorting (FACS) (BD Bioscience) to isolate cells successfully 
expressing Cas9, cells were allowed to recover for an additional 24hr period and then transfected with the 
guide RNA targeting exon 1 of the SELENOM gene (sequence: CCGGATTGGAACCGTCTTCG, IDT) and 
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universal tracrRNA (IDT). Following another 24hr recovery period, cells were subjected to a second round 
of sorting for GFP-positive cells and then cultured in 96-well plates at a density of 1 cell/well. We verified 
the knockout efficacy by Western blot assay and PCR after colonies formed (Fig. 2-4B). Primers for 
verification of SELENOM that flank exon 1 were purchased from IDT (Forward: 5'- GATTTGGGTGGGAT 
GTCAGT-3', reverse: 5’- TCATGCGGCTGGGAAATAA -3'). DNA Sequencing data shows that there is a 
deletion of ‘TCTTCGAG’ from the 342nd to the 349th basepair of the SELENOM cDNA sequence. 
Western blot 
   After different treatments, samples were prepared by sonication using CelLytic MT buffer (Sigma) 
with protease/phosphatase inhibitors (Cell signaling) and cleared by centrifugation. Samples consisting of 
40 µg of protein were resolved on a denaturing 4-20% SDS-PAGE gel (Bio-Rad) and transferred to 
polyvinylidene fluoride membranes by electroblotting. The membranes were then blocked in Odyssey 
blocking buffer in PBS (LI-COR) for 30 minutes and incubated with specific primary antibodies at 4°C 
overnight. Blots were incubated with species-specific IR-dye coupled secondary antibodies (LI-COR) at 
room temperature for half an hour in the dark the next day. The signals were detected and analyzed by 
Image Studio Version 5.2 (LI-COR Odyssey).  
Calcium imaging  
   Changes in intracellular Ca2+ level were determined by the Ca2+ indicator Fluo-4/AM (Invitrogen) using 
confocal imaging (Nikon). An appropriate amount of cells were seeded to sterile cover slips one day before 
imaging. These cells were loaded with 5 µM Fluo-4/AM (Invitrogen) for 45 minutes at 37°C. Cells were then 
washed three times with live cell imaging solution (Invitrogen) before imaging using a Nikon Diaphot 
microscope attached to a Nikon PCM 2000 in the Kakaʻako Health Sciences Microscopy and Imaging Core 
Facility. Images were recorded using excitation at 488 nm, emission at 515–565 nm, and 40× oil lenses. 
Responses were recorded as a time course, consisting of confocal images taken at 5 sec/interval for a total 
of either 150 or 300 sec. Tg (2 µM) or leptin (100 nM) was added at 30 sec. Ionomycin (1 µg/ml) (Sigma) 
was used as a positive control to elicit maximal Ca2+ responses. At least twelve random cells were selected 
for each experiment. Fluo-4 signals associated with individual cells were assessed via ImageJ software as 
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fluorescence was converted to signal intensity and normalized to baseline (F/F0) for quantification purposes. 
Data are presented for at least three independent experiments.  
Statistical analysis 
   Data were analyzed using unpaired Student’s t-tests (for 2 groups) or two-way ANOVA (for > 2 
groups) with Bonferroni post-test analysis (GraphPad Prism Software7.0). Results were represented as 
means ± SEM of at least three independent experiments. P values were calculated with the appropriate 
statistical tests using GraphPad Prism software 7.0. A significant difference is considered to be present at 
*p<0.05. 
 
Results 
   SELENOM protein level is increased by leptin treatment. To investigate the effect of leptin on 
SELENOM expression and determine whether hypothalamic leptin resistance happens prior to the 
development of obesity in Selenom-/- mice,   we conducted a leptin challenge on 10-week-old wild-type and 
Selenom-/- mice with comparable body weights. Hypothalamic tissue was isolated and then subjected to 
Western blot analysis for SELENOM expression and leptin-induced Stat3 activation. Results demonstrated 
that SELENOM protein level was increased by leptin treatment in wild-type hypothalamic tissues (Fig. 2-
5A, B). Western blot analyses also revealed that Stat3 phosphorylation induced by leptin treatment was 
significantly decreased in the Selenom-/- group compared to the wild-type group (Fig. 2-5 A, C). Taken 
together, these results suggest that SELENOM is a leptin-responsive gene and promotes hypothalamic 
leptin signaling. 
 
   SELENOM promotes leptin signaling in mHypoE-44 cell line. To further define the function of 
SELENOM in leptin signaling, we performed a set of experiments using the mHypoE-44 cell line, an 
immortalized cell line derived from embryonic mouse hypothalamic neurons that expresses AGRP and NPY 
[132]. A construct encoding SELENOM short hairpin RNA (shRNA) was used to generate a stably 
transfected mHypoE-44 cell line where SELENOM expression was knocked down approximately 75% upon 
21 
 
induction with doxycycline. Meanwhile, we also generated a Selenom-/- mHypoE-44 cell line with 
CRISPR/Cas9 editing. SELENOM knockdown and Selenom-/- mHypoE-44 cells were treated with leptin at 
100 nM for 45 min and assessed for Stat3 signaling by Western blot. As expected, leptin treatment 
increased pStat3 levels and this induction was impaired by SELENOM deficiency (Fig. 2-6).  To further 
confirm the role of SELENOM in leptin signaling, we overexpressed SELENOM in mHypoE-44 cells. Cells 
overexpressing SELENOM had notably higher levels of pStat3 compared to the control cells with leptin 
treatment (Fig. 2-7). Interestingly, total Stat3 levels were also elevated by leptin treatment in cells 
overexpressing SELENOM.  Taken together, these results verify that SELENOM is a positive regulator of 
leptin signaling.   
 
   SELENOM regulates the cytosolic Ca2+ level change induced by leptin. Our previous findings 
revealed that SELENOM has neuroprotective function and regulates Ca2+ homeostasis under conditions 
of oxidative stress [95]. In addition, it has been also demonstrated that leptin treatment induces 
hyperpolarization and leads to a reduction in cytosolic Ca2+ levels in AGRP neurons [110, 133].  As 
mentioned previously, mHypoE-44 cells have been reported to express AGRP and may display some 
features characteristic of AGRP neurons [132]. Subsequent observation by live imaging under confocal 
fluorescent microscopy showed that leptin treatment led to a corresponding reduction of baseline 
cytosolic Ca2+ in the control group, and this effect was abrogated in SELENOM shRNA-expressing cells 
(Fig. 2-10 A, B). Similar results were found in our Selenom-/- cell line, as leptin failed to reduce cytosolic 
Ca2+ levels (Fig. 2-10 C, D). The results reveal that SELENOM is potentially a critical key in Ca2+ 
regulation in terms of leptin signaling. 
 
   Increased ER stress in SELENOM-deficient hypothalamic cells. ER stress is notable for its 
causative role in leptin resistance [134]. There are several pharmacological reagents which can induce 
ER stress through several different mechanisms, such as tunicamycin, thapsigargin (Tg), and Brefeldin A. 
In the present study, Tg was used to induce ER stress. It is a specific inhibitor of the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) which can induce a decrease in ER Ca2+ 
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levels and cause the accumulation of unfolded proteins in the ER. To study the specific role of SELENOM 
in ER stress, mHypoE-44 cells were first transfected with SELENOM shRNA and then subjected to Tg (1 
µM) treatment for 4 hours. The cells were then prepared for Western blot analysis. Upon ER stress, 
PERK pathways activate CCAAT/-enhancer-binding protein homologous protein (CHOP), a pro-apoptotic 
transcriptional factor [135]. Significant higher levels of pPERK and CHOP levels were observed in 
response to Tg treatment in cells where SELENOM was knocked down compared to control cells (Fig. 2-
8A). Overexpression of SELENOM had the opposite effect (Fig. 2-9), which supports the conclusion that 
SELENOM regulates ER stress pathways in hypothalamic cells. 
 
   SELENOM regulates the cytosolic Ca2+ level change induced by Tg. To further test the 
relationship between SELENOM and the regulation of intracellular Ca2+ signaling, we carried out live 
imaging experiments of hypothalamic cells with Tg treatment. There was a more significant increase of 
intracellular Ca2+ level in cells with SELENOM knockdown in response to Tg compared to control cells 
(Fig. 2-11A, B). The increase in Ca2+ influx was potentially from the culture media or intracellular Ca2+ 
stores. We further repeated this experiment in Ca2+-free extracellular media. Intracellular Ca2+ responses 
displayed the same pattern but the difference relative to the control group was smaller (Fig. 2-11C, D). 
These results provide evidence that increased cytosolic Ca2+ in response to ER stress may be from 
intracellular stores such as the ER. Similar effects were found in Selenom-/- cells (Fig. 2-12). Parallel to 
our previous Western blot results, these results suggest that SELENOM plays an important role in 
regulating Ca2+ store signaling. 
 
Discussion 
 
   With the rise in prevalence of obesity and type 2 diabetes, much effort has been made to investigate 
the mechanisms that regulate body weight and energy homeostasis.  The hypothalamus is the central site 
that governs food intake and energy expenditure. Within the hypothalamus, neurons in the ARC nucleus 
monitor energy status by sensing hormones and nutrients in the circulating blood, such as leptin. Leptin 
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can initiate several signaling cascades of which JAK2-Stat3 signaling is the most prominent. The notion 
that hypothalamic selenoproteins are critical in regulating leptin signaling was verified recently using 
conditional knockout of Sec-tRNA (Trsp) mouse models with rat-insulin-promoter-driven-cre (RIP-Cre) 
and specific pancreatic-β cell-cre (Ins1-Cre), respectively[4]. This TrspRIP KO model disrupted Trsp 
expression in certain hypothalamic cells and pancreatic β cells. The authors evaluated the metabolic 
phenotypes in these two mouse models when challenged with a high fat diet. TrspRIP KO mice exhibited 
severe disruptions in glucose tolerance, insulin resistance, and leptin resistance, whereas the TrspIns1 KO 
mice did not display the same metabolic abnormalities. Moreover, upon leptin treatment, the TrspRIP KO 
mice displayed a much lower hypothalamic pStat3 level than the control group, indicating that 
hypothalamic leptin resistance occurs upon disruption of selenoprotein synthesis in hypothalamus. In our 
study, we demonstrated that the intraperitoneal injection of leptin increased levels of SELENOM in wild-
type mice, which indicates that SELENOM is a leptin-responsive gene. Moreover, compared to wild-type 
mice, Selenom-/- mice displayed decreased hypothalamic Stat3 activation in response to leptin, indicative 
of leptin resistance. Studies in vitro further verified that SELENOM is involved in promoting leptin 
signaling. These findings indicate that hypothalamic SELENOM plays an important role in leptin signaling. 
   To date, established causes of leptin resistance include inflammation, autophagy and ER stress. The 
ER is a dynamic organelle that is involved in protein folding, fatty acid and phospholipid synthesis, and 
Ca2+ homeostasis. Cellular disturbances that cause the accumulation of misfolded proteins trigger 
activation of the UPR. The tight link of ER stress and obesity was first reported by Ozcan et al [136]. 
Since then, accumulating studies have provided further evidence that hypothalamic ER stress promotes 
leptin resistance [116]. In diet-induced obesity models (DIO), UPR signaling pathways, including PERK, 
IRE1α, and ATF6, have been found  overactivated, in conjunction with impaired leptin signaling. In 
addition, mice receiving an intracerebroventricular injection of ER stress inducers developed leptin 
resistance along with an increase food intake and body weight gain [116]. Similar results were also found 
in vitro that leptin-induced pStat3 signaling was significantly reduced when treated with ER stress 
inducers [129]. Alternatively, when ER stress was ameliorated by ER stress inhibitors, such as 
tauroursodeoxycholic acid and 4-phenylbutyrate, ER stress makers were downregulated and leptin 
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sensitivity was rescued in DIO mice [116, 124, 137]. Our findings provide novel evidence revealing that 
SELENOM is a modulator of leptin signaling in the hypothalamus while inhibiting the ER stress response.   
   Within the cell, the ER is the major storage site for intracellular Ca2+, whereas cytosolic Ca2+ 
concentrations are kept at low levels via the actions of many transporters, pumps and exchangers. ER 
stress can be triggered by abnormalities in Ca2+ signaling. Severe ER stress promotes Ca2+ efflux 
between the ER and mitochondria, which causes modification in mitochondria membrane potential and 
permeability, leading to apoptosis [138]. In our study, we hypothesized that the impaired leptin sensitivity 
and elevated ER stress response observed in Selenom-/- samples may largely related to disrupted Ca2+ 
signaling. Our Ca2+ imaging data revealed that SELENOM deficiency mitigated the reduction of 
intracellular Ca2+ in response to leptin and promoted the Ca2+ release from the intracellular Ca2+ store 
under the treatment of ER stress inducer. However, the precise mechanisms still need to be explored. As 
mentioned above, SELENOM levels were significantly reduced in transgenic mice overexpressing the 
human mutant PS2 gene that causes familial Alzheimer’s disease (FAD) [92]. PS2 is documented to play 
a critical role in calcium homeostasis via altering the expression or sensitivity of the ryanodine receptor 
(RyR), inositol 1,4,5-trisphosphate receptor (IP3R), and  SERCA pump [139, 140]. Moreover, presenilins 
are enriched in ER mitochondria-associated membranes and alterations in PS2 expression affects Ca2+ 
shuttling between ER and mitochondria [141, 142]. There is accumulating evidence indicating that Ca2+ 
homeostasis is significantly affected by the redox status of the surrounding environment. Disturbances in 
redox balance and ER stress increase cytosolic Ca2+ levels and enhance the release of Ca2+ from ER via 
different channels. Redox modification of RyRs leads to ER Ca2+ leak and ROS was found to specifically 
sensitize IP3Rs through a thiol group(s) to promote Ca2+ efflux [143-145]. It was also interesting to find 
that selenium-supplementation reduced the IP3R-operated Ca2+ release from intracellular store [146]. 
SELENOM, a selenoprotein displaying antioxidant functions, was demonstrated regulate the cytosolic 
Ca2+ levels in the present study. Some of our preliminary data has also shown that SELENOM is co-
expressed with IP3R1 and RyR3 in the wild-type mouse brain and the protein levels of IP3R1 and RyR3 
are significantly reduced in the Selenom-/- mouse brain. All these findings indicate that SELENOM may 
affect the redox environment and in turn, affect the calcium signaling via different calcium channels, IP3R 
and/or RyRs.    
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          In conclusion, our findings provide new information in regard to the potential role of SELENOM in 
hypothalamic leptin signaling, ER stress, and Ca2+ signaling. We demonstrated that SELENOM deficiency 
impairs hypothalamic leptin signaling both in vivo and in vitro, indicating that SELENOM is a positive 
regulator of leptin signaling. Moreover, our data also revealed that SELENOM abrogates the induction of 
ER stress and Ca2+ store release in response to Tg.  
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Figure 2-1. Summary of leptin signaling pathways. The binding between leptin (Ob) and leptin 
receptor (ObR) stimulates ObR dimerization and autophosphorylation of JAK2. In turn, JAK2 
phosphorylates two key tyrosine residues on the ObR, Ty958 and Tyr1138, and then activate ERK and 
Stat3, respectively. In parallel, JAK2 can also activate IRS, PI3K, and AKT pathway. When 
phosphorylated, Stat3 forms a dimer and translocates into the nucleus, where it regulates the 
transcription of target genes, including POMC and SOCS3. SOCS3 and PTP1B are negative regulators of 
leptin signaling.  
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                                                                                                                Adapted from St-Pierre et al., 2012 
Figure 2-2. Summary of normal and leptin resistance physiology. In normal conditions, leptin derived 
from adipose tissue, plays a critical role in the regulation of food intake and energy expenditure. It 
increases the expression of anorexigenic peptides and inhibits the expression of the orexigenic peptides. 
On the contrary, leptin resistance in the hypothalamus is a major reason for the failure of leptin to reduce 
feeding behavior and stimulate energy metabolism. 
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Figure 2-3. Summary of normal and ER stress conditions. ER stress can activate a variety of cellular 
processes via signaling pathways termed the unfolded protein response (UPR) in order to restore ER 
functions. In an unstressed state, these three proteins are inactive via association with glucose-regulated 
protein 78 (GRP78), the most abundant chaperone in the ER. In response to accumulation of unfolded 
proteins, GPR78 dissociates from these three ER stress sensors and translocates to the ER lumen for 
protein folding. This dissociation changes the conformation of PERK, IRE1α, and ATF6, leading to their 
activation                                                                                      
 
                                          
Adapted from Tadic et al., 2014 
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Figure 2-4. Manipulation of SELENOM expression in mHypoE-44 cells. A, Western blot analysis of 
SELENOM expression with shRNA-mediated knockdown. B, Western blot analysis of SELENOM 
expression with CRISPR/Cas9-mediated knockout. C, Western blot analysis of SELENOM expression in 
SELENOM-overexpressing (+pSELENOM) cells. D, Western blot analysis of leptin (Ob) signaling with Ob 
overexpressing (pObR) cells. Results shown represent the means ± SEM (unpaired Student’s t-tests or 
two-way ANOVA with Bonferroni post-tests) for at least three independent experiments. ***p<0.0001, 
compared to control group. 
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Figure 2-5. SELENOM is a leptin-responsive gene that promotes hypothalamic leptin signaling in 
vivo. A, Western blot analysis of leptin-induced signaling in hypothalamic tissue derived from 10 week old 
male wild-type and Selenom-/- mice of comparable body weight. Animals were fasted overnight, 
challenged with an intraperitoneal injection of leptin (Ob) (1 μg leptin / gram body weight), and sacrificed 
60 min thereafter (n = 3-4). B, Leptin-induced Stat3 phosphorylation was significantly diminished in 
Selenom-/- samples. C, Leptin treatment significantly elevated SELENOM protein levels in wild-type 
samples. Results shown represent the means ± SEM (two-way ANOVA with Bonferroni post-tests) for at 
least three independent experiments. *p<0.05, compared to control group.  
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Figure 2-6. SELENOM promotes leptin signaling in mHypoE-44 cells. A, C, Western blot analysis of 
leptin-induced signaling in mHypoE-44 cells. Cells were serum-starved for 4 hours and then challenged 
with 100 nM leptin for 45 min. B, D, Levels of leptin-induced Stat3 phosphorylation was significantly 
reduced in samples with both shRNA-mediated knockdown (B) and CRISPR/Cas9-mediated knockout (D) 
of SELENOM as compared to the NTC shRNA control and normal control cells, respectively. Results 
shown represent the means ± SEM (two-way ANOVA with Bonferroni post-tests) for at least three 
independent experiments. **p<0.01, ***p<0.001 compared to control group. 
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Figure 2-7. SELENOM overexpression promotes leptin signaling in mHypoE-44 cells. A, Treatment 
with SELENOM overexpression plasmid promotes leptin-stimulated increase in pStat3. B, Quantification 
of Stat3 phosphorylation normalized to total Stat3 levels. C, Quantification of Stat3 levels normalized to β-
Actin levels. Results shown represent the means ± SEM (two-way ANOVA with Bonferroni post-tests) for 
at least three independent experiments. **p<0.01, ***p<0.001 compared to control groups. 
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Figure 2-8. Treatment with SELENOM siRNA augments Tg-induced ER stress response A, 
Treatment with SELENOM siRNA augments Tg-induced increase in p-PERK and CHOP. B, 
Quantification of PERK phosphorylation normalized to β-Actin levels. C, Quantification of CHOP levels 
normalized to β-Actin levels. Results shown represent the means ± SEM (two-way ANOVA with 
Bonferroni post-tests) for at least three independent experiments. ***p<0.001 compared to control groups. 
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Figure 2-9. Overexpression of SELENOM reduces Tg-induced ER stress response. A, 
Overexpression of SELENOM reduces Tg-induced ER stress response in mHypoE-44 neurons.  B, 
Quantification of PERK phosphorylation normalized to β-Actin levels. Results shown represent the means 
± SEM (two-way ANOVA with Bonferroni post-tests) for at least three independent experiments. 
***p<0.001, compared to control groups. 
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Figure 2-10. SELENOM deficiency impedes leptin-induced reduction of cytosolic Ca2+ levels in 
mHypoE-44 cells. A, C, Confocal images showing cytosolic Ca2+ levels before (t = 0s) and after 
treatment with leptin (t = 300s). B, D, Both shRNA-mediated knockdown (B) and CRISPR/Cas9-mediated 
knockout (D) of SELENOM impeded the leptin-induced reduction of cytosolic Ca2+ observed in control 
samples. Results shown represent the means ± SEM for at least three independent experiments. 
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Figure 2-11. SELENOM knockdown in mHypoE-44 cells alters Ca2+ release from intracellular stores 
in response to Tg. A, SELENOM level is reduced after 48 hr DOX treatment in cells stably transfected 
with SELENOM shRNA. B, Ca2+ levels at baseline (t = 0s) and peak responses (t = 72s) to Tg in each 
group. C, SELENOM knockdown increases cytosolic Ca2+ levels to Tg (2 µM). D, Cytosolic Ca2+ 
responses to Tg when cells were incubated in PBS without Ca2+. Results shown represent the means ± 
SEM for at least three independent experiments. 
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Figure 2-12. CRISPR/Cas9-mediated Selenom-/- in mHypoE-44 cells alters Ca2+ release from 
intracellular stores in response to Tg. A, Ca2+ levels at baseline (t = 0s) and peak responses (t = 72s) 
to Tg in each group. B, Selenom-/- increases cytosolic Ca2+ levels to Tg (2 µM) C, Cytosolic Ca2+ 
responses to Tg when cells were incubated in PBS without Ca2+. Results shown represent the means ± 
SEM for at least three independent experiments. 
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CHAPTER 3.   SUBCELLULAR LOCATION AND  
INTERACTION PARTNERS OF SELENOM 
 
Abstract 
   SELENOM is an ER-resident thiol-disulfide oxidoreductase implicated in the Ca2+ homeostasis, ER 
stress, and energy metabolism. ER is well known as the major storage site for Ca2+ by which ER can 
interact and share information with the cytosol and other organelles, such the mitochondria. Ca2+ flux from 
the ER to the mitochondria plays an essential role in regulating both ER and mitochondrial functions. 
Therefore, ER-mitochondria connection sites, named mitochondria associated ER membranes (MAMs), 
are essential for many biological processes that occur in these two organelles. In the present studies, we 
performed subcellular fractionation using wild-type mouse brains and found that SELENOM was not only 
detected in ER, but also localized in MAMs and the mitochondria. We then conducted a screening of 
SELENOM-binding partners using co-immunoprecipitation and LC-MS/MS. Results determined two 
interaction partners of SELENOM, microtubule associated protein 6 (MAP6) and phosphate 
cytidylyltransferase 1, choline, alpha (PCYT1A), which are indicated in Ca2+ signaling and 
phosphatidylcholine biosynthesis.  
 
Introduction 
   The ER is a central organelle responsible for lipid biosynthesis, protein folding, and post translational 
modifications. Moreover, the ER is the major storage site for Ca2+, by which it can export signal 
information to the cytosol and other organelles, the mitochondria in particular [147, 148]. Ca2+ flux from 
the ER to the mitochondria plays an essential role in regulating mitochondrial functions, including energy 
metabolism, Ca2+ homeostasis, and apoptotic signaling. Elevated levels of Ca2+ within the mitochondria 
promotes the Krebs cycle, adenine nucleotide transporters, and pyruvate dehydrogenase, leading to 
increased ATP production [149-152]. The accumulation of misfolded protein leads to increased ER-
mitochondria contact and elevated Ca2+ efflux to the mitochondria, thereby stimulating energy production 
[153]. However, high levels of Ca2+ can also induce modifications in mitochondria membrane potential 
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and permeability, leading to apoptosis via cytochrome C [138]. Dysregulation of the Ca2+ flux during this 
process has been involved in many disorders, including metabolic diseases, cancer, and 
neurodegeneration.  
   Therefore, Ca2+ flux modulated by ER-mitochondria connection sites is essential for biological 
processes occurring in these two organelles. The physical interaction sites between the ER and 
mitochondria, first discovered in 1950 by electron microscopy in rat tissues, are termed as mitochondria 
associated ER membranes (MAMs) [148]. These highly dynamic structures regulate the bidirectional 
exchange of lipids, Ca2+, and other metabolites. Moreover, MAMs are implicated in mitochondria 
bioenergetics and morphology, therefore coordinating the homeostasis between ER and mitochondria. 
   Herein, we set out to assess SELENOM subcellular localization and speculate that SELENOM may 
also localize in MAMs which are involved in Ca2+ regulation. Moreover, SELENOM may have some potential 
interaction partners related to Ca2+ homeostasis and MAMs regulation. In these present studies, we found 
that SELENOM was not only detected in ER, but also localized in MAMs and mitochondria. Interestingly, 
we found two interaction partners of SELENOM, MAP6 and PCYT1A, which are involved in Ca2+ signaling 
and phosphatidylcholine biosynthesis. 
 
Methods and Materials 
 
Chemicals and antibodies   
   Primary antibodies used in these experiments are rabbit anti-COX-IV (1:1000; Cell signaling, 4850), 
mouse anti-VDAC1 (1:500; Santa Cruz, sc-390996), rabbit anti-IP3R (1:500; Santa Cruz, sc-377518), 
mouse anti-SERCA2 (1:500; Santa Cruz, sc-376235), mouse anti-BRCA1 (1:500, Santa Cruz, sc-6954), 
mouse anti-STOP (1:500, Santa Cruz, sc-53513), mouse anti- PCYT1A (1:500, Santa Cruz, sc-376107), 
rabbit anti-PDI (1:1000, cell signaling,2446), mouse anti-FACL-4 (1:500, Santa Cruz, sc-365230), and 
mouse anti-β-Actin (1:5000; Cell Signaling, 3700). Species specific secondary antibodies were purchased 
from LI-COR.                                 
Animals 
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   Male wild-type and Selenom-/- mice based on C57BL/6N background were born, bred, and raised in 
the University of Hawai‘i Vivarium (N≥5 for each group). Mice were sacrificed with CO2 at week 10 and 
mouse whole brains were snap-frozen for future analysis. The method of hypothalamic dissection was 
described in Chapter 2. 
Cell culture  
   The hypothalamic cell line mHypoE44 (Cellution) and CRISPR/Cas9 stable knockout cell line 
(Described in Chapter II) were maintained in DMEM (Sigma) with 10% FBS (Invitrogen) and 1% penicillin 
in a humidified incubator with 5% CO2 at 37°C.   
Subcellular fractionation   
   Mouse brains were homogenized and centrifuged twice at 800 x g to remove unbroken cells and 
nuclei. Supernatants were then subjected to centrifugation three times at 10,000 x g to remove the 
plasma membrane, lysosomes, microsomes, and cytosol. The collected pellet containing the crude brain 
mitochondria was resuspended and transferred to an ultracentrifuge tube containing Percoll and 
mitochondria resuspending buffer. We centrifuged the samples at 95,000 x g to separate pure 
mitochondria from mitochondria-associated membranes (MAMs). A dense band containing the purified 
mitochondria fraction localizes at the bottom with a white band containing the MAMs fraction above it. 
These bands were further washed and collected to get pure mitochondria and MAMs. Fractions from the 
experiments above were subjected to Western Blot to verify the purity (Figure 3-1). 
Co-immunopreciptation and mass spectrometry 
   Brain samples were lysed in CelLytic MT (Sigma) with protease/phosphatase inhibitors (Cell 
signaling) and subject to a centrifugation at 14,000 x g for 15 minutes to remove cellular debris.  Whole 
cell lysates (200 µg) were pre-cleared by incubating with Magnetic Protein G-coupled Dynabeads 
(Thermo Fisher Scientific Life Science) for 10 minutes. Meanwhile, magnetic Protein G-coupled 
Dynabeads (50 ul) were incubated with 3µg SELENOM Abs for 10 minutes, as recommended by the 
manufacturer. After crosslinking the antibody to Dynabeads using BS3, pre-cleared lysates were 
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incubated with Dynabeads (50 μl) bound to the SELENOM antibody overnight at 4°C. Unbound protein 
samples were collected and the protein complex were eluted from beads the following day. Eluates were 
separated via SDS/PAGE and the polyacrylamide gels were stained with SilverXpressTM   silver staining kit 
(Thermo Fisher Scientific Life Science) according to the manufacturer’s instruction. Three bands with 
visible difference between two groups were excised and sent out for LC-MS/MS analyses by Applied 
Biomics (Hayward, CA, USA).  
Western Blot 
  Described in Chapter II. 
Statistical analysis 
  Described in Chapter II. 
 
Results  
   Identification of SELENOM subcellular localization. We speculated that SELENOM may also 
reside at the site of physical communication between ER and mitochondria, MAMs.  To examine this 
notion, we isolated ER, MAMs, crude mitochondria, and pure mitochondria fractions from wild-type mouse 
brains following a well-established subcellular fractionation protocol described in methods section. The 
subcellular fractions and whole cell lysates were prepared and then subjected to Western blot analysis, 
probing for specific organelle markers, including Long-chain fatty-acid CoA synthases (FACL-4) as a 
MAMs marker, cytochrome c oxidase subunit 4 (COX4) as a mitochondria marker, Voltage-dependent 
anion channel 1 (VDAC1) as a mitochondria and MAMs marker, and protein disulfide isomerase (PDI) as 
an ER marker [154-157]. VDAC1, as a mitochondrial and MAMs marker, should be expressed in the 
crude mitochondria fraction and extremely enriched in the pure mitochondria fraction. It could also be 
present in the MAMs fraction. The ER marker, PDI, localizes in the ER and plays essential role in protein 
folding. Western blot analysis shows that the MAMs fraction is enriched for FACL-4 and pure 
mitochondria fraction is enriched in VADC1, indicating the high purity of the MAMs and pure mitochondria 
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(Fig. 3-1). Our data also verified the purity of the crude mitochondria and ER fractions. SELENOM 
expression was detected in the ER, MAMs, and mitochondria, suggesting a new subcellular map of 
SELENOM. These results are also consistent with the notion that SELENOM localizes in the MAMs and 
may potentially contribute to the transportation of Ca2+ and other metabolites between the ER and 
mitochondria.  
 
   Identification of SELENOM interacting partners.  Some studies have revealed interaction partners 
of SELENOM, such as Galectin-1, Notch2nl, Nenf proteins, and Mtus proteins [158-160]. However, there 
have been no further studies on the functions and underlying mechanisms of SELENOM and its 
interactions partners. Herein, we anticipate that SELENOM may interact with proteins that contribute to 
leptin signaling, Ca2+ regulation, and energy metabolism. A screening of SELENOM-binding partners was 
conducted using protein derived from 10-week-old wild-type mouse brain with corresponding protein from 
Selenom-/- mouse brain as a negative control. Lysates from both samples were incubated with anti–
SELENOM-coated beads, which co-immunoprecipitate (co-IP) SELENOM and its binding partners. Target 
protein complexes were then eluted and subjected to SDS-PAGE, followed by silver staining (Fig. 3-2A). 
Three prominent bands were observed and hence excised from both wild-type and Selenom-/- samples at 
molecular weights corresponding to 40kDa, 70kDa, and 140 kDa for further analysis. These gel slices 
samples were then digested and analyzed by LC-MS/MS for potential binding partners. This analysis led 
to the identification 15 SELENOM-interaction partners that only appeared in the wild-type samples (Table 
2). To further verify the interactions, we first chose the proteins of which molecular weight are close to 
40kDa, 70kDa, and 140 kDa and performed a literature search of their known function. We found that 
several proteins are largely involved in the energy metabolism, including PCYT1A, MAP6, and Brca1. The 
same co-IP experiments using anti–SELENOM-coated beads were conducted and followed by Western 
blot analysis, probing for those potential interacting proteins of SELENOM. Results confirmed two 
candidates of particular interest, MAP6 and PCYT1A. We also conducted co-IP experiments using anti–
MAP6-coated beads to further confirm the interaction between SELENOM and MAP6 by Western blot 
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analysis (Fig. 3-2B, C). Interestingly, MAP6 was also detected when pulling down PCYT1A, suggesting a 
potential protein complex formed by these three proteins (data not shown). 
 
Discussion 
   Ca2+ released from the ER to the mitochondria plays a critical role in several mitochondrial functions 
and is a major determinant of energy metabolism and cellular fate. As the main storage compartment for 
Ca2+, the ER maintains a specific environment containing chaperones and folding enzymes for protein 
folding and maturation.  All these biological processes require a high concentration of Ca2+ in the ER 
which is maintained by the ER Ca2+ uptake system, SR/ER Ca2+ transport ATPase b (SERCA2b). This 
store will release Ca2+ through two gated Ca2+ release channels, inositol 1, 4, 5-trisphosphate receptors 
(IP3Rs) and the ryanodine receptors (RyRs) in response to various stimulation.  
   The ER forms abundant membrane contact sites with the plasma membrane and the other 
organelles, including mitochondria, endosomes, Golgi, lysosomes, lipid droplets, and peroxisomes [161].. 
Electron microscopy and fluorescence microscopy of the MAMs in cells and yeast reveal a cleft of 10-50 
nm between the ER and mitochondria [162]. However, the physical structures of MAMs are dynamic and 
highly regulated by different status of cells. In addition, the ER-mitochondria contacts become closer in 
the early phases of ER stress [163].  Csordas et al. enhanced the ER-mitochondria association using a 
synthetic linker protein and found that bringing the ER closer to the mitochondria significantly increases 
mitochondria Ca2+ uptake [164]. All these findings delineate the tight relationships of MAMs and Ca2+ 
regulation. However, the mechanisms by which MAMs undergoes this plasticity is still elusive and the 
impact on the mitochondrial Ca2+ is highly variable.  
   ER-resident selenoproteins include SELENOF, SELENOK, SELENOM, SELENON, SELENOS, 
SELENOT, and the type-2 iodothyronine deiodinase. Among these selenoproteins, SELENOK, 
SELENOM, and SELENON have been indicated in regulating Ca2+ signaling [95, 100, 101, 165]. 
SELENOK was reported as an ER-membrane protein that promotes Ca2+ influx during activation of 
immune cells, and SELENOK deficiency causes impaired Ca2+ flux due to a defect in palmitoylation of 
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inositol-1, 4, 5-triphosphate receptor (IP3R), a Ca2+ channel protein. SELENON was implicated in ER 
redox balance and Ca2+ homeostasis via SERCA2 pump [101]. The function of a protein is closely 
correlated with its subcellular location. Herein, we performed subcellular fractionation to verify the 
compartmentalization of SELENOM. We showed that,in addition to localizing to the ER (and Golgi), 
SELENOM can also be detected in MAMs and mitochondria, suggestive of a role in regulating Ca2+ flux 
between the ER and mitochondria. Although the precise mechanism has yet to be established, it is highly 
possible that SELENOM regulates Ca2+ flux from ER to mitochondria by affecting specific ER Ca2+ 
channels via a redox mechanism. 
   Structure studies of SELENOM suggest that the flexible C-terminal region is a potential binding site of 
SELENOM for protein substrates [78]. Moreover, a 3D structure model of SELENOM reveals three well 
conserved residues (F59, L82, and L84) that act as putative hub nodes for retaining pivotal protein-
protein interactions [79]. In a previous study, SELENOM with a modified structure was used to screen for 
the potential interaction partners by the yeast two-hybrid system. The results suggested an interaction 
between SELENOM and Galectin-1, a protein which prevents neurodegeneration [159]. However, in our 
co-IP experiments using mouse brain samples, we could not reproduce the same results. This may be 
due to environmental differences between the yeast two-hybrid system and endogenous mouse brain 
tissue. Our LC-MS/MS analysis and further co-IP experiments determined two binding partners of 
SELENOM, MAP6 and PCYT1A. MAP6 encodes microtubule-associated protein 6 and is related to 
microtubule stabilization under different conditions, including low temperature and treatment of 
depolymerizing reagents [166, 167]. MAP6-/- mice display severe behavioral disorders that are associated 
with synaptic plasticity defects [168]. The functions of MAP6 are largely regulated via its phosphorylation 
by Ca2+/calmodulin-dependent protein kinase II (CaMKII), which is regulated by Ca2+/calmodulin complex 
and is necessary for Ca2+ homeostasis [169, 170]. It has been reported that Ca2+/calmodulin competes 
with the microtubule for binding sites of MAP6 during synaptic activation [171]. A more recent report 
found that MAP6 interacts directly with both T-Complex-Associated-Testis-Expressed 1 (Tctex1) and the 
C-terminus of Cav2.2/N-type Ca2+ channels, indicating a specific role of MAP6 to modulate Ca2+ signaling 
in neurons[172]. This study also suggests that MAP6 is largely related to Ca2+ signaling in neurons. 
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   PCYT1A, phosphocholine cytidylyltransferase, is an essential rate-limiting and regulatory enzyme in 
phosphatidylcholine (PC) synthesis. PC is the most abundant phospholipid and maintains the structure 
and functionality of all cellular membranes. PCYT1A, largely resident in the nucleus, becomes more 
active form on translocating to the ER membrane for PC biosynthesis [173]. Interestingly, PC biosynthesis 
and PCYT1A have been largely correlated with ER stress pathways. Inhibition of PC biosynthesis using a 
thermo-sensitive mutation in PCYT1A at non-permissive temperature led to PC depletion, and in turn 
induced the expression of ER-stress-related protein CHOP, indicating that PC depletion by inactivation of 
PCYT1A may induce an ER stress response [174]. Upon the activation of UPR, XBP-1 is spliced to the 
active form XBP-1s which acts as a transcription factor and regulates the transcription of genes involved 
in ER membrane biosynthesis, protein transportation [175]. Sriburi et.al reported that XBP-1s-induced ER 
biogenesis in fibroblasts enhanced PC biosynthesis and increased activities of PCYT1A and CPT [175]. 
Further experiments revealed that the effect of XBP-1s in the CDP-choline pathway is primarily based on 
its regulation of PCYT1A activity [83]. PC is also the major phospholipid of mitochondrial membranes and 
needs to be imported from other organelles, mainly from ER [176]. During transport, PC can be detected 
at contact sites between ER and mitochondria [176, 177], suggesting MAMs are a key site involved in 
lipid translocation to mitochondria [178]. SELENOM, localizing in MAM and interacting with PCYT1A, may 
potentially affect the synthesis and transport of PC from ER to mitochondria, and in turn, modulate the 
dynamic morphology and functions of mitochondria. 
   We found that SELENOM localizes to MAMs, which suggests that SELENOM may regulate Ca2+ 
signaling between ER and mitochondria. Moreover, we identified two interaction partners of SELENOM, 
MAP6 and PCYT1A, which are involved in Ca2+ signaling and phosphatidylcholine biosynthesis. 
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Figure 3-1. Subcellular localization of SELENOM in mouse brain. Western blot of subcellular fractions 
prepared from wild-type and Selenom-/- brain. Proteins were detected with rabbit anti-PDI (ER marker), 
mouse anti-FACL-4 (MAMs marker), mouse anti-VDAC1 (mitochondria and MAMs marker), rabbit anti-
COX 4 (mitochondria marker), and mouse anti-SELENOM antibodies. ER: endoplasmic reticulum; Mito_c: 
crude mitochondrial fraction; Mito_p: pure mitochondrial fraction; MAMs: mitochondria-associated 
membranes. Results shown represent for at least three independent experiments. 
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Figure 3-2. SELENOM interacts with MAP6 and PCYT1A in mouse brain. A, wild-type and Selenom-/- 
brain lysates were incubated with anti-SELENOM coated magnetic beads overnight and eluted. Eluates 
were then separated by SDS-PAGE and stained by sliver staining kit. Gels slices were excised for each 
lane around 40kDa, 70kDa, and 140kDa. B, Interactions between SELENOM and PCYT1A were 
investigated by Co-immunoprecipitation with wild-type and Selenom-/- brain samples. C, Interactions 
between SELENOM and MAP6 were investigated by co-immunoprecipitation with wild-type and Selenom-
/- brain samples. 
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Table 2.  Candidate interaction partners of SELENOM in wild-type samples  
 
*MW: molecular weight (kDa). 
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CHAPTER 4. SELENOM DELETION AFFECTS THE  
THIOREDOXIN SYSTEM 
 
Abstract 
   As a member of TXN superfamily, SELENOM shares the similar structure (CXXU) with TXN at its 
active site and has been implicated in redox signaling and energy metabolism. In Chapter 2, we have 
presented evidence that SELENOM is involved in leptin signaling, induced ER stress, and Ca2+ signaling. 
However, SELENOM-related genes and genetic pathways have yet to be characterized. Herein, we 
performed microarray analysis using both hypothalamic tissue and mHypoE-44 cells to the identify genes 
and signaling pathways mostly affected by SELENOM deficiency. Among the identified differentially 
expressed genes (DEGs), thioredoxin interacting protein (TXNIP) is of particular interest as its specific 
function is related to the TXN system. TXN and TXNRD activity were both found altered by SELENOM 
deficiency as well. Taken together, our findings demonstrate that hypothalamic TXN system is regulated 
by SELENOM and potentially contributes to hypothalamic leptin signaling. 
 
Introduction 
   SELENOM is a thiol-disulfide oxidoreductase that is highly expressed in the brain. Specifically, our 
group has found that SELENOM is highly expressed in several discrete brain regions, including the 
arcuate and paraventricular nuclei of the hypothalamus and some other regions of brain. Among all these 
regions, paraventricular nucleus (PVN) and arcuate nucleus (ARC) of hypothalamus are of most interest 
due to their involvement in energy metabolism regulated by leptin. SELENOM is implicated in leptin 
signaling both in vitro and in vivo. Selenom-/- mice exhibit significant weight gain with increased circulating 
leptin levels and impaired leptin sensitivity in the ARC of hypothalamus [81]. Aforementioned results in 
Chapter 2 have demonstrated that SELENOM is a leptin-responsive gene and can regulate leptin 
signaling, ER stress, and Ca2+ signaling. 
   Thus, to further investigate the genes and signaling pathways affected by SELENOM deletion, we 
conducted microarray analysis on both hypothalamic cell and tissue samples. Our analyses revealed that 
TXNIP was significantly downregulated in both hypothalamic tissue and mHypoE-44 cells. Moreover, TXN 
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activity was significantly decreased by SELENOM deficiency. Taken together, our studies verify that 
SELENOM regulates the TXN antioxidant activities, which may contribute to its function in hypothalamic 
leptin signaling.  
 
Methods and Materials 
Chemicals and antibodies   
   Primary antibodies used in these experiments are mouse anti-TXNIP (1:1000; NOVUS, NBP1-54578) 
and mouse anti-β-Actin (1:5000; Cell Signaling, 3700). Species specific secondary antibodies were 
purchased from LI-COR.                                  
Animals 
   Described in Chapter 2. 
CRISPR/Cas9-mediated Selenom-/- in mHypoE-44 cells 
      Described in Chapter 2. 
Microarray analysis 
   RNA was isolated from hypothalamic tissue and mHypoE-44 cells using the RNaqueous micro kit 
(Ambion). Samples were then sent to the University of Hawai‘i Cancer Center Genomics Core Facility for 
microarray analysis. RNA integrity was first validated on an Agilent 2100 Bioanalyzer. 100 ng of total RNA 
was then used for the GeneChip Whole-transcript assay followed by hybridization to Clariom S Mouse 
Arrays (Affymetrix, Santa Clara, CA, USA). Arrays were washed, stained, and scanned using a GeneChip 
Fluidics Station 450 and a GeneChip Scanner (Affymetrix). CEL files generated from Clarion S Mouse 
Arrays were analyzed by Transcriptome Analysis Console software v4.0 (Affymetrix).  
Antioxidant activity assays 
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   Hypothalamus and cell samples were harvested and then 20 µg total protein were subjected to the TXN 
and TXNRD activity assessment by TXN activity fluorescent assay kit (IMCO, Sweden) and TXNRD assay 
kit (Sigma, MO, USA) according to the manufacturer’s instructions. TXN activity was determined by the 
reduction of insulin disulfides by reduced TXN with TXNRD and NADPH as the electron donor. Excess 
TXNRD and NADPH were provided to keep TXN at reduced state. During this reaction, fluorescence 
intensity at 515-525 nm will be altered from low to high level. Different doses of human thioredoxin 1 (hTXN-
1) were used to generate standard curve by calculating the rate of reaction (Δfluorescence per minute). 
TXN activity of the sample were determined using the formula given by the standard curve. The TXNRD 
activity was assessed using a colorimetric assay which is based on the reduction of 5,5¢-dithiobis(2-
nitrobenzoic) acid (DTNB) with NADPH to 5-thio-2-nitrobenzoic acid (TNB), which  is measured at 412 nm.  
TXNRD activity of samples was determined by measuring the increase in absorption at 412 nm. One unit 
of mammalian TXNRD in this experiment will cause an increase in A412 of 1.0 per minute per ml at pH 7.0 
at 25 °C (Sigma). 
Western Blot 
  Described in Chapter 2. 
Statistical analysis 
  Described in Chapter 2. 
 
Results 
   The expression of TXNIP was downregulated on knocking out SELENOM. To further investigate 
genes and signaling pathways affected by SELENOM deficiency, a gene expression study was conducted 
using microarray assay on mHypoE-44 cells and hypothalamic tissue samples from 10 week-old mice. Total 
RNA from the hypothalamic tissue (n=4) and mHypoE-44 cells (n=3) was isolated and then subjected to 
microarray assay using Clariom S Array Kit. Transcriptome Analysis Console software v3.0 was used to 
analyze differential gene expression profiles. In order to determine the differentially expressed genes 
(DEGs), we set two filter criteria: a fold change of greater than 50% and p-value <0.01 between the wild-
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type and Selenom-/- groups (Fig. 4-1). There are 1983 DEGs in mHypoE-44 cells and 167 DEGs in the 
hypothalamus which passed the filter criteria. Among those DEGs, 11 transcripts were significantly altered 
in both hypothalamic tissue and mHypoE-44 cells (Fig. 4-2A). One transcript of particular interest was the 
TXNIP, a known negative regulator of TXN and mammalian target of rapamycin (mTOR)-dependent 
signaling [179]. TXNIP expression was significantly decreased by SELENOM deficiency in both 
hypothalamic tissue and mHypoE-44 cells, which was verified by Western blot analysis (Fig. 4-2B-E). The 
results revealed that SELENOM deficiency induced a significant downregulation of TXNIP level, which 
could be a compensatory response to SELENOM ablation. 
 
   SELENOM deficiency significantly diminishes TXN activity. TXNIP, an endogenous inhibitor of 
TXN, plays an important role in the regulation of the TXN system, which consists of TXN, TXNRD, and 
NADPH. This major antioxidant system protects cells from oxidative stress through its thiol-reducing 
functions [179]. As described above, TXNIP is downregulated by knocking out SELENOM in both 
hypothalamic tissue and cell line. Thus, to further determine the effect of SELENOM in regulating TXN 
system activity, both TXN and TXNRD activity assays were performed on hypothalamic tissue and 
mHypoE-44 cells. In hypothalamic tissues, TXN activity was significantly decreased with no differences in 
TXNRD activity (Fig. 4-3A, B).  However, in mHypoE-44 cells, SELENOM deficiency impeded TXN activity 
and TXNRD activity at the same time (Fig. 4-3C, D). The reason why SELENOM deficiency would impact 
TXNRD activity in cell culture but not hypothalamic tissue is still unknown. It could be related to the 
differences between an actual brain structure and an immortalized cell line. The results support the notion 
that SELENOM regulates the hypothalamic TXN system.  
 
Discussion 
   To further elucidate the underlying mechanism of how SELENOM regulates leptin signaling, a 
microarray analysis was conducted in hypothalamus and mHypoE-44 cells to identify SELENOM-related 
genes and pathways.  Our analyses identified  167 DEGs in hypothalamic tissue and 1983 DEGs in 
mHypoE-44 cells when filter criteria was set at a fold change of greater than 50% and p-value <0.01 
between control and Selenom-/- samples (Figure 4-1B). The hypothalamus is a heterogeneous brain 
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structure that contains 34 different neuronal clusters and 11 non-neuronal clusters [180]. This diversity of 
cell types present in the hypothalamus may largely contribute to the smaller number of DEGs observed in 
hypothalamic tissue.  Among these 11 DEGs, we found that TXNIP was notably downregulated by 
SELENOM deficiency. The TXN system, consisting of TXN, TXNRD, and NADPH, is a key antioxidant 
system which controls cellular redox homeostasis. TXNs contain a redox active site (CXXC) and are kept 
in reduced form by TXNRDs using electrons transferred from NADPH. Disturbances of the TXN system 
have been associated with a wide range of health problems, including cancers, neurodegeneration, 
cardiovascular diseases, and metabolic disorders [181, 182].  One major regulatory influence upon this 
antioxidant system is TXNIP, an endogenous negative regulator of TXN [183]. Oxidized TXNIP binds to 
the reduced TXNs through a disulfide exchange, causing TXNs inactivation. TXNIP has emerged as a 
critical component in regulating cellular redox balance, particularly in relation to metabolic syndrome [184, 
185]. Its level can be upregulated by ER stress via PERK and IRE1α signaling pathways in β cells, 
leading to activation of interleukin-1β production by the NLRP3 inflammasome [186-188]. This process is 
the main determinant of ER stress-mediated β cell death. Hypothalamic TXNIP also plays a critical role in 
nutrient sensing and energy metabolism, as downregulation of TXNIP protects against a HFD [184]. It 
was further demonstrated that conditionally overexpressing TXNIP in AGRP neurons leads to a reduction 
of energy expenditure and HFD-induced obesity, whereas TXNIP deficiency promotes leptin sensitivity 
[185]. In addition to TXNIP, TXN, and TXNRD also play significant roles in lipid homeostasis and energy 
metabolism [189-192]. For example, Rajalin et al. showed that both TXN and TXNRD activities were 
increased during the adipocyte differentiation, whereas inhibitors of adipogenesis decreased TXNRD 
activity [193]. In the present study, TXNIP was downregulated by knocking out SELENOM, indicative of a 
compensatory response to increase TXN activity and re-establish cellular redox homeostasis. 
   Among all the DEGs in hypothalamic tissue, TXNIP is the only gene of which protein levels were 
confirmed to decrease in Selenom-/- samples. However, there are some other genes of potential interest 
due to their specific functions involved in energy metabolism (Table 3). The CCAAT/enhancer binding 
protein delta (Cebpd) is a transcription factor that regulates many biological processes including cell 
differentiation, proliferation, and cell death. Cebpd was found to affect adiposity and body weight in 
female animals. Additionally, female Cebpd−/− animals also showed a decrease in circulating insulin level 
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with no effect on leptin levels. However, leptin levels are reduced in Cebpb-/- mice, indicating that Cebpd 
is also associated with leptin regulation [194]. Lipocalin-2 (Lcn2), also known as neutrophil gelatinase-
associated lipocalin (NGAL), is well characterized as a mediator of inflammatory processes [195]. It is a 
major regulator in intestinal inflammation and in turn, regulates the intestinal metabolic immune 
interactions. In adipose tissue, increased Lcn2 levels were found in ob/ob mice, db/db mice, and mice 
with HFD [196]. Moreover, it is associated with insulin resistance in hepatocytes and β cells via regulation 
of inflammatory responses [197, 198]. Another DEG, cyclin dependent kinase inhibitor 1A (Cdkn1a), is a 
cyclin-dependent kinase inhibitor that acts as a regulator of cell cycle progression at G1 and S phase via 
its inhibitory function on activity of cyclin-cyclin-dependent kinases. Expression of Cdkn1a is regulated by 
the tumor suppressor protein 53 (p53) and appears to play a critical role in the DNA damage and cell 
cycle. These candidates give us some potential targets to explore the biological functions of SELENOM in 
the future. 
   Taken together, our findings conclusively demonstrate that the hypothalamic TXN system is regulated 
by SELENOM and that this potentially contributes to hypothalamic leptin signaling. Moreover, besides 
TXNIP, several additional DEGs were identified by our microarray studies, and these include genes 
involved in energy homeostasis, inflammation, and cell cycle. These results provided us with several 
putative pathways affected by SELENOM deletion and offer valuable directions for our future studies in 
SELENOM. 
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Figure 4-1. Venn diagrams showing the number of DEGs between control and Selenom-/- samples. 
Filter criteria was set as fold change of greater than 50% and a p-value<0.05 (A) or p-value<0.01(B).   
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Figure 4-2. The expression of TXNIP was downregulated by knocking out SELENOM. A, Venn 
diagram (top) showing the number of DEGs determined by the microarray analysis on mHypoE-44 cells 
and hypothalamic tissue. Transcripts showing a fold change of greater than 50% and p-value <0.01 
between control and Selenom-/- samples were considered to be DEGs. 11 DEGs were affected in both 
hypothalamic tissue and mHypoE-44 cells. Heatmap plot (bottom) of these 11 DEGs, with upregulation 
and downregulation of fold change represented by red and blue, respectively. B, D, Western blot analysis 
of TXNIP protein levels in hypothalamic tissue (B) and mHypoE-44 cells (D). C, E, TXNIP protein levels 
were significantly diminished by SELENOM deficiency in both hypothalamic tissue (C) and mHypoE-44 
cells (E). Results shown represent the means ± SEM (unpaired Student’s t-tests) for at least three 
independent experiments. *p<0.05, **p<0.01 compared to control group. 
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Table 3.  Summary of Differentially Expressed Genes  
Affected by SELENOM Deficiency  
 
Gene 
Hypothalamus mHypoE-44  
Functions Fold 
change 
P value Fold 
change 
P value 
Cdkn1a -3.29 0.0014 1.99 0.0013 Cell cycle [199] 
Lcn2 -2.76 0.0010 -2.82 3.14E-05 NF-kB pathway, 
Inflammation [200] 
TXNIP -1.84 0.0002 -3.22 4.65E-06 Oxidative stress 
Inflammation [186],  
Cebpd -1.64 0.0005 -3.46 3.63E-07 Inflammation [201], 
Adipocyte differentiation 
[202] 
Btnl5-ps -1.64 0.008 1.89 0.0003 NF-κB signaling [203] 
Plin4 -1.56 0.0039 3.19 8.77E-06 Lipid accumulation [204] 
Hck -1.52 0.003 -3.12 6.94E-05 Inflammation [205] 
Tbrg3 1.71 0.0017 1.97 0.0008 Unknown 
Ret 1.66 0.0022 -2.68 0.0003 Cancer [206] 
Ccser1 1.53 0.0036 2.17 0.0001 Unknown 
2410089E
03Rik 
1.52 0.0096 2.41 1.43E-05 Unknown 
 
Table 3. Summary of differentially expressed genes affected by SELENOM deficiency. Transcripts 
showing a fold change of greater than 50% and p-value <0.01 between control and Selenom-/- samples 
were considered to be DEGs. 11 DEGs were affected in both hypothalamic tissue and mHypoE-44 cells, 
with upregulation and downregulation of fold change represented by red and green. 
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Figure 4-3. SELENOM deficiency significantly impacts TXN activity in hypothalamic tissue and 
mHypoE-44 cells. A, C, Levels of TXN activity were significantly reduced by SELENOM deficiency in 
both hypothalamic tissue (A) and mHypoE-44 cells (C). B, D, Levels of TXNRD activity were unaffected 
by SELENOM deficiency in hypothalamic tissue (B), but were significantly diminished in Selenom-/- 
samples in mHypoE-44 cells (D). Results shown represent the means ± SEM (unpaired Student’s t-tests) 
for at least three independent experiments. **p<0.01 compared to control group.  
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CHAPTER 5   CONCLUSION 
 
Summary of the Findings  
   We found that SELENOM expression in wild-type hypothalamic tissue was increased in response to 
leptin treatment, indicating SELENOM is a leptin-responsive gene. Selenom-/- mice displayed impaired 
leptin sensitivity, as leptin-induced Stat3 phosphorylation was largely reduced compared to wild-type 
mice. Similar results were found in hypothalamic mHypoE-44 cells. Moreover, leptin treatment led to a 
reduction of baseline cytosolic Ca2+ in the control group, and this effect was attenuated by knocking out or 
knocking down SELENOM. We then assessed the effects of SELENOM on ER stress, a well-known 
cause of leptin resistance. In response to thapsigargin, increased ER stress was found in SELENOM-
deficient mHypoE-44 cells compared to the control group, indicating that SELENOM suppresses 
hypothalamic ER stress. Additionally, thapsigargin also induced a robust increase in cytosolic Ca2+ when 
SELENOM was knocked down or deleted. Furthermore, our findings add novel evidence that SELENOM 
is a positive modulator of the TXN system in the hypothalamus, which can potentially contribute to 
hypothalamic leptin signaling. Microarray analysis on hypothalamic tissues and cells revealed one DEG of 
particular interest, TXNIP, a known negative regulator of TXN. In addition, TXN activity was significantly 
decreased by SELENOM deficiency. Lastly, we assessed SELENOM subcellular localization and 
identified two novel SELENOM interaction partners, MAP6 and PCYT1A. Results from subcellular 
fractionation determined that SELENOM also resides in MAMs and the mitochondria, in addition to the 
ER. 
   Thus, our findings conclusively delineate the positive role of SELENOM in leptin signaling and TXN 
activity in hypothalamus (Fig. 5-1). Moreover, our results revealing new subcellular localizations and 
interacting partners of SELENOM point to new directions for investigating in the biological functions of 
SELENOM. 
 
General Discussion and Future Directions 
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   One of the main findings of this work is that SELENOM deficiency impairs leptin signaling. However, in 
our microarray studies, we did not find any changes in the mRNA levels of the two best established negative 
regulators of leptin signaling, SOCS3 and PTP1B. The decreased leptin sensitivity in Selenom-/- samples 
may be due to other factors. Interestingly, among 11 DEGs from the microarray assay, 4 transcripts, 
implicated in inflammation, including Lcn2, TXNIP, Cebpd, and Hck, were significantly downregulated in 
Selenom-/- samples. Multiple studies have revealed that activation of proinflammatory signaling pathways 
in hypothalamus promotes leptin resistance [124, 207-209]. Lcn2 is of particular interest in regulating the 
inflammation pathways, especially NF- κB pathways. NF-κB is a transcription factor that regulates 
inflammatory signaling pathways. Activation of hypothalamic NF-κB-mediated signaling inhibits Stat3 
activation, leading to impaired leptin signaling, and increased expression of interleukin 1 (IL-1), IL-6, and 
TNFα [207, 210]. Lcn2 has been characterized as an anti-inflammatory cytokine/adipokine in obesity and 
inflammation [198]. Lcn2 deficiency results in increased activation of NF- κB signaling induced by 
lipopolysaccharides (LPS) [211]. In addition, Lcn2 has been reported to suppress inflammation via inhibition 
of the NF-κB pathway in retinal degeneration and uveitis [212, 213]. We speculate that SELENOM 
deficiency may activate the NF-κB pathway and inhibit Stat3 activation, leading to impaired leptin signaling. 
However, questions still remain as to whether and how SELENOM deficiency affects the hypothalamic 
immune system via Lcn2. Future experiments will determine changes and functions of proinflammatory 
cytokines in Selenom-/- hypothalamic tissue and how these cytokines contribute to leptin signaling. 
   Mitochondria have an essential role in ROS generation and mitochondrial bioenergetics is largely 
determined by Ca2+ signaling via MAMs. These ER-mitochondria contact sites are rich in proteins involved 
in ER-mitochondria tethering, phospholipid metabolism, Ca2+ signaling, and protein folding. Intriguingly, 
multiple ER chaperones that localize to MAMs are TXN family members or selenoproteins. Endoplasmic 
reticulum resident protein 44 (ERp44), containing a TXN domain, interacts with IP3R1 and competes with 
binding immunoglobulin protein (BiP)/Grp78 for the binding sites [98, 99]. ERp44 overexpression reduced 
IP3R1-mediated Ca2+ release and in turn, prevented Ca2+-induced apoptosis via IP3R1 [98]. Another two 
TXN family members, TXN-related transmembrane protein 1 (TMX1) and endoplasmic reticulum DNA J 
domain-containing protein 5 (ERdj5), both act on SERCA2b but have opposite functions. TMX1 is 
enriched in the MAMs and exhibits an inhibitory function on SERCA2b. TMX1 promotes Ca2+ flux from the 
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ER to mitochondria upon binding to and inactivating this Ca2+ uptake channel, therefore affecting 
mitochondrial bioenergetics [214, 215]. ERdj5 also contains TXN domains and acts as a reductase in the 
ER. It activates SERCA2b under stressed conditions, thereby maintaining ER Ca2+ levels and protecting 
cells from mitochondrial dysfunction [216]. Like ERdj5, SELENON can reduce luminal cysteines of 
SERCA2b and then activate this Ca2+ channel [101]. In our study, SELENOM, a member of the TXN 
superfamily, was found to localize in MAMs and constitutes an important component of the hypothalamic 
TXN system. Additionally, we have promising data showing that SELENOM deficiency promotes Ca2+ 
release from the ER in hypothalamic cells in response to Tg-induced ER stress.  MAMs are dynamic 
structures that will change their key parameters, size of the area and the gap width between the ER and 
the mitochondria in response to various disturbances. We speculate that SELENOM deficiency will help 
to expand MAMs and promote the Ca2+ flux under a stressed state. Moreover, we have observed that 
IP3R1 and RyR3 are co-expressed with SELENOM in the mouse brain and may be affected by 
SELENOM deficiency. Therefore, SELENOM-mediated increase of Ca2+ flux to the mitochondria may also 
potentially result from its interaction with Ca2+ channels or pumps, such as SERCA and IP3R. This 
process may subsequently regulate the function of mitochondria, including ATP generation, ROS 
generation, and apoptosis signaling. However, the present study did not determine: 1) the subcellular 
compartment where cytosolic calcium is pumped in response to leptin in mHypoE-44 cells; 2) whether 
SELENOM affects mitochondrial calcium levels; or 3) whether SELENOM influences the morphology of 
MAMs. Further experiments are necessary to decipher the influence of SELENOM at MAMs with respect 
to Ca2+ signaling, and mitochondria function.  
   Meanwhile, we observed that SELENOM interacts with MAP6 and PCYT1A, two key proteins  
implicated in microtubule stabilization and phosphatidylcholine biosynthesis, respectively, indicating that 
SELENOM may be involved in modulation of ER-related membrane biosynthesis. As mentioned above, 
PCYT1A is the rate-limiting enzyme in PC synthesis and its activity is increased upon translocation to the 
ER [173]. Moreover, PC depletion induced by inactivation of PCYT1A increases the expression of CHOP, 
indicating that PCYT1A deficiency may induce an ER stress response and influence ER membrane 
biosynthesis [144]. We propose that SELENOM binds to and stabilizes PCYT1A in the ER to promote its 
function, whereas SELENOM deficiency will induce PC depletion via inactivation of PCYT1A. This is 
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consistent with our current findings that the expression of CHOP was increased when knocking down 
SELENOM. However, questions still remain as to the mechanisms by which SELENOM influences the 
functions of these two interacting partners in biological processes. Further investigation of SELENOM will 
be necessary to delineate the specific relationship between SELENOM and of these two interaction 
partners in the context of oxidative stress.  
     In addition to energy metabolism, SELENOM has also been implicated in the field of cancer. Selenium 
treatment in the SELENOM overexpression transgenic rat model was reported to activate the MAPK 
pathway [94]. Consequentially, hyperactivation of the MAPK pathway has also been reported  in 
hepatocellular carcinoma (HCC). Based on this possible correlation between SELENOM and HCC, 
Guariniello et al. evaluated the SELENOM expression in two HCC cell lines, HepG2 and Huh7, compared 
to the normal hepatocytes. They found an elevated level of SELENOM in HCC cell lines by real-time PCR 
and Western Blot, suggesting the involvement of SELENOM in HCC [79]. Further investigation confirmed 
this finding in tumor samples from patients with HCC by immunohistochemistry, which suggests that 
SELENOM expression in liver tissues of HCC patients could be a potential prognostic tool for 
understanding HCC progression [217]. Herein, we have determined that SELENOM is a positive regulator 
of TXN system. The TXN system plays a critical role in the regulation of cell growth and cell survival. One 
established point of regulation is the inhibition of MAPK signaling mediated by the binding of reduced 
TXN1 to apoptosis signal-regulating kinase 1 (ASK-1) [218]. ASK-1 is an upstream regulator of MAPK 
signaling which is critical in oxidative stress-induced apoptosis [219]. In addition, TXN1 levels are 
increased in many human cancers [220-222]. Cancer cells use TXNs as protectors against oxidative 
stress-induced apoptosis. This may at least partially explain why SELENOM is highly expressed in HCC 
compared to normal cells. Since SELENOM is a positive modulator of TXN system, it may be also a 
potential target for cancer therapy. Further investigation is necessary to delineate this novel redox 
signaling mediated by SELENOM and its functions in cancers and other redox imbalance-related 
disorders.   
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Figure 5-1. Hypothetical model of SELENOM function. SELENOM is an ER-resident oxidoreductase 
which is an important component of the hypothalamic TXN system. Genetic ablation of SELENOM 
disturbs ER homeostasis and impedes leptin signaling, leading to impairments in energy metabolism. 
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